<SEC-DOCUMENT>0001121404-23-000010.txt : 20230427
<SEC-HEADER>0001121404-23-000010.hdr.sgml : 20230427
<ACCEPTANCE-DATETIME>20230427113942
ACCESSION NUMBER:		0001121404-23-000010
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230427
DATE AS OF CHANGE:		20230427

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		23853423

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a6kcoverpagepressreleaseq1.htm
<DESCRIPTION>6-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ica5b8debd8764273805dec57e8e9c327_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM&#160;6-K</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE&#160;13a-16&#160;OR&#160;15d-16</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the month of April 2023</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#58;&#160;001-31368</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANOFI</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Translation of registrant&#8217;s name into English)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">46, avenue de la Grande Arm&#233;e, 75017 Paris, FRANCE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of principal executive offices)</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 20-F&#160;&#160;&#9746;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;&#160;&#9744;</font></div><div style="margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule 101(b)(1)&#58;&#160;&#160;&#9744;</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule 101(b)(7)&#58;&#160;&#160;&#9744;</font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule&#160;12g3-2(b)&#160;under the Securities Exchange Act of 1934.</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If &#8220;Yes&#8221; marked, indicate below the file number assigned to the registrant in connection with Rule&#160;12g3-2(b)&#58;&#160;82-&#160;</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, Sanofi issued the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.035%"><tr><td style="width:1.0%"></td><td style="width:20.574%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.226%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit No.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Press release dated April 27, 2023&#58; Strong Q1 growth driven by Specialty Care, Vaccines and CHC </font></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.747%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.635%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; April 27, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANOFI</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#47;s&#47; Alexandra Roger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexandra Roger</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Head of Securities Law and Capital Markets</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressreleaseq12023english.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i2456b270d3a64714a6867e4852c38438_1"></div><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Press Release                                                              </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><img alt="imagea.jpg" src="imagea.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:165px"></div><div style="padding-left:4.5pt"><font><br></font></div><div style="padding-left:4.5pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:18pt;font-style:italic;font-weight:400;line-height:112%">Strong Q1 growth driven by Specialty Care, Vaccines and CHC</font></div><div style="margin-bottom:9pt;margin-top:15pt;padding-left:13.5pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Paris, April 27, 2023</font></div><div style="margin-bottom:3pt;padding-left:4.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Q1 2023 sales growth of 5.5% at CER and business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:700;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%"> growth of 11.9% at CER</font></div><div style="padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.9pt">Specialty Care grew 18.3% driven by Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (&#8364;2,316 million, +39.7%) and Rare Disease </font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.9pt">Vaccines up 15.2% reflecting recovery of Booster and Travel vaccines and COVID vaccine shipments in Europe </font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.9pt">General Medicines sales lower (-11.4%) mainly due to Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> and divestments, core assets growing 1.6%</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.9pt">CHC sales of &#8364;1,495 million increased by 11.2% with price and favorable phasing as main contributors</font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.9pt">Business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> of &#8364;2.16 up 11.3% on a reported basis and 11.9% at CER </font></div><div style="margin-top:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.9pt">IFRS EPS of &#8364;1.60 (down 0.6%)  </font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Key R&#38;D milestones and regulatory achievements in Q1</font></div><div style="margin-top:3pt;padding-left:15.1pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:5.9pt">ALTUVIIIO&#8482; approved by the FDA for the treatment of adults and children with hemophilia A</font></div><div style="margin-top:3pt;padding-left:15.1pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:5.9pt">Two additional approvals for Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%">in Europe (EoE from 12 years and AD in 6 months and older)</font></div><div style="margin-top:3pt;padding-left:15.1pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:5.9pt">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> accepted for review in the U.S. and Japan for the treatment of CSU</font></div><div style="margin-top:3pt;padding-left:15.1pt;text-indent:-10.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%;padding-left:6.6pt">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:112%"> met primary and all secondary endpoints in its first phase 3 study in patients with COPD</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Progress on Corporate Social Responsibility strategy in Q1</font></div><div style="padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:6.6pt">Sanofi partnering with Ghana Ministry of Health to improve affordable access to diabetes care</font></div><div style="padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:6.6pt">Net Zero</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> by 2045 and updated scope 3 targets validated by Science Based Targets Initiative (SBTi)</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:15.1pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Full-year 2023 business EPS guidance confirmed </font></div><div style="margin-bottom:3pt;padding-left:15.1pt;padding-right:2.15pt;text-align:justify;text-indent:-10.8pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.9pt">Sanofi expects 2023 business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to grow low single digit</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> at CER, barring unforeseen major adverse events. Applying average April 2023 exchange rates, the currency impact on 2023 business EPS is estimated between -5.5% to -6.5%</font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Paul Hudson, Sanofi Chief Executive Officer,  commented&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">&#8220;We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses. Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> continues its compelling performance and is on track to achieve its &#8364;10 billion sales objective for this year. The unique product profile of Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9.96pt;font-style:italic;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">was further underscored by highly positive pivotal results in uncontrolled chronic obstructive pulmonary disease, which we are looking forward to discuss with regulators. We are also advancing our early-to-mid stage pipeline and plan to feature several promising candidates at upcoming R&#38;D investor events. For the remainder of the year, we are confident in our business outlook, while navigating the impact from generic versions of Aubagio</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%">, our last meaningful patent expiry this decade, with generics entering the U.S. market at the end of Q1. With the U.S. launch of ALTUVIIIO&#8482; now underway and the anticipated roll-out of Beyfortus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.47pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:115%"> in time for the RSV season later this year, we keep executing on our Play to Win growth strategy.&#8221; </font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_4"></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS net sales reported</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;10,222m</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+5.7%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+5.5%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS net income reported</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;1,995m</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-0.7%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">_</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IFRS EPS reported</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;1.60</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-0.6%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">_</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Free cash flow</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;1,537m</font></td><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-10.0%</font></td><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">_</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business operating income</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;3,333m</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+8.7%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+9.3%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Business net income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2,699m</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.3%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.9%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-right:-4.05pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business EPS</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8364;2.16</font></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.3%</font></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.9%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 7). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-GAAP financial measure (definition in Appendix 7). The consolidated income statement for Q1 2023 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4&#59; (2) refer to ESG section for Sanofi Net Zero definition&#59; (3) 2022 business EPS was &#8364;8.26&#59; (4) Free cash flow is a non-GAAP financial measure (definition in Appendix 7)</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  1                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">.</font></div><div id="i2456b270d3a64714a6867e4852c38438_505"></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">2023 first-quarter summary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">----------------------------</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Unless otherwise indicated, all percentage changes in sales in this press release are stated at CER</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">---------------------</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2023, Sanofi sales were &#8364;10,222 million, up 5.7% on a reported basis. Exchange rate movements had a positive effect of 0.2 percentage points. At CER, company sales were up 5.5%. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Global Business Units</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">First-quarter 2023 net sales by Global Business Unit (variation at CER&#59; &#8364; million&#59; % of total sales)</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><img alt="chart-7f33e0548ec048fabf5a.jpg" src="chart-7f33e0548ec048fabf5a.jpg" style="height:270px;margin-bottom:5pt;vertical-align:text-bottom;width:654px"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Business operating income</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter 2023 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">business operating income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (BOI) increased 8.7% to &#8364;3,333 million. At CER, BOI increased 9.3%. The ratio of BOI to net sales increased 0.9 percentage point (ppt) to 32.6% (32.8% at CER). </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Acquisitions and major collaborations</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 13, 2023, Sanofi and Provention Bio entered into an agreement under which Sanofi agreed to acquire Provention Bio for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction will add </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TZIELD</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(teplizumab-mzwv), an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi&#8217;s core asset portfolio in General Medicines. The acquisition is a strategic fit for Sanofi at the intersection of the company&#8217;s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes. This transaction is subject to customary closing conditions and is expected to close in the second quarter of 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On April 11, 2023, Sanofi announced a simplification of the contractual arrangements relating to the development and commercialization of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Beyfortus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (nirsevimab) in the U.S. Under the new and updated arrangements, Sobi has terminated its participation agreement with AstraZeneca, and Sanofi and AstraZeneca have updated the Collaboration Agreement so that Sanofi has full commercial control of Beyfortus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in the U.S. Consequently, Sanofi has recorded an intangible asset for the Fair Value of the additional U.S. rights acquired from AstraZeneca, which will be amortized below Business Net Income. Sanofi has simultaneously entered into a direct royalty agreement with Sobi, whereby Sanofi will pay Sobi a royalty on U.S. net sales of Beyfortus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. This transaction with Sobi is a financial transaction, whereby Sanofi transfers a royalty interest and recognizes a financial liability for the Fair Value of the U.S. royalties in the balance sheet. The liability will reduce over time as we pay the U.S. royalties to Sobi. Subsequent re-measurement of the liability will be accounted for through income statement below Business Net Income. </font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to territories outside the U.S., the existing Collaboration Agreement between AstraZeneca and Sanofi continues to govern that relationship (with the exception of China, which is now defined as a &#8220;major market&#8221;, with a 50&#47;50 profit&#47;loss share with AstraZeneca). </font></div><div id="i2456b270d3a64714a6867e4852c38438_499"></div><div style="margin-top:6pt"><font><br></font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">See Appendix 7 for definitions of financial indicators</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  2                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Sales by geographic region</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sanofi sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United States</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4,069</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+11.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2,576</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">+8.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of the World</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">3,577</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">-2.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;of which China</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">755&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-14.0&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">U.S., </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">first-quarter sales increased 11.8% (to &#8364;4,069 million), supported by the strong performance of Specialty Care driven by Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">more than offsetting sales decline of Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Europe,</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> first-quarter sales were up 8.4% (to &#8364;2,576 million) driven by Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Nexviadyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Praluent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, and COVID vaccine shipments as well as double-digit growth of CHC. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Rest of World region, </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">first-quarter sales decreased 2.1% (to &#8364;3,577 million), mainly reflecting lower sales in China which was partially offset by the growth of Specialty Care driven by Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Rare Disease as well as CHC in the region. Sales in </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">China</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> decreased 14.0% to &#8364;755 million reflecting a COVID-driven slow start early in the year. In addition, sales of Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> were negatively impacted by the Volume Based Procurement (VBP) related price cuts, partially offset by higher sales of Specialty Care products and Praluent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </font></div><div id="i2456b270d3a64714a6867e4852c38438_7"></div><div style="margin-bottom:6pt;margin-top:9pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Biopharma</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Biopharma segments include the Global Business Units Specialty Care, General Medicine and Vaccines. Please also see Appendix 1 and 2 for the comprehensive segment reporting. </font></div><div id="i2456b270d3a64714a6867e4852c38438_13"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Specialty Care</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,316&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-top:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+39.7&#160;</font></td><td style="border-top:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Aubagio</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:133%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">419&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-16.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Myozyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:133%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">&#47; Lumizyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:133%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-3.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Fabrazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:133%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cerezyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:133%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+26.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eloctate</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-15.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Alprolix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:133%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+12.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Aldurazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:133%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nexviazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#47;Nexviadyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+163.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Jevtana</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-21.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sarclisa</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+33.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:133%">Cablivi</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:133%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+23.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Enjaymo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">TM</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter, </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (collaboration with Regeneron) sales increased 39.7% to &#8364;2,316 million. In the U.S., Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales of &#8364;1,759 million (up 43.3%) were driven by continued strong demand in the approved indications, atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), eosinophilic esophagitis and prurigo nodularis. Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> total prescriptions (TRx) increased 32% (y</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">ear-over-year</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) and new-to-brand prescriptions (NBRx) grew 45%. In Europe, first-quarter Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales grew 32.2% to &#8364;277 million reflecting continued growth in AD, asthma and CRSwNP. In the Rest of the World region, first-quarter sales reached &#8364;280 million, up 27.8%, driven mainly by sales in Japan and China. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Aubagio</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales decreased 16.9% in the first quarter to &#8364;419 million reflecting the expected entry of generics in the U.S. from mid-March. Sales in </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the Rest of the World region were down a</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">s a result of generic competition in Canada</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Europe, teriflunomide generic competition is expected in the fourth quarter of 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter sales of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Nexviazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#47;Nexviadyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;81 million, up 163.3% in the first quarter (of which &#8364;56 million in the U.S.) driven by </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Myozyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#47;Lumizyme </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">conversion in the eligible Pompe population (late-onset disease) and new patient accruals. </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Myozyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#47;Lumizyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales decreased 3.0% to &#8364;228 million reflecting conversion in Nexviazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;&#47;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Nexviadyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> partially offset by favorable purchasing patterns in the Rest of the World region.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  3                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Fabrazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales increased 11.8% to &#8364;246 million, reflecting new patient accruals and growth in all three geographic regions. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cerezyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were up 26.7% to &#8364;196 million, driven by strong sales growth in the Rest of the World region benefitting from favorable purchasing patterns. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Eloctate</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;118 million in the first quarter, down 15.9% reflecting lower sales in the U.S. due to competitive pressure and fluctuation in inventory levels. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ALTUVIIIO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">T</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">M</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, a once-weekly new class of factor VIII therapy for hemophilia A that offers significant bleed protection, was launched at the end of March in the U.S.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Alprolix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were up 12.0% to &#8364;125 million driven by the U.S. and the Rest of the World region. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sarclisa</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;87 million, up 33.8%, reflecting growth in all three geographic regions. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Jevtana</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales decreased 21.4% to &#8364;79 million due to the entry of generic competition in Europe at the end of March 2021 and lower sales in the U.S., reflecting increased competition. In the U.S., Jevtana</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> is currently covered by four Orange Book listed patents US 7,241,907, US 8,927,592, US 10,583,110 and US 10,716,777. Sanofi filed patent infringement suits under Hatch-Waxman against generic filers asserting the &#8216;110 patent, the &#8216;777 patent and the '592 patent in the US District Court for the District of Delaware. Sanofi has reached settlement agreements with most of the defendants and the suit against the only remaining defendant Sandoz is ongoing. In August 2022, the district court dismissed Sanofi&#8217;s infringement claim related to the &#8216;592 patent. A 3-day trial took place on January 11-13, 2023, and Sandoz has agreed not to launch any generic cabazitaxel product until the earlier of a district court decision in favor of Sandoz or four months after the completion of the post-trial briefing.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Cablivi</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales increased by 23.9% to &#8364;58 million in the first quarter supported by the performance across geographies. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales of</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> Xenpozyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, the first and only enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase, were &#8364;18 million in the first quarter generated in the U.S. and Europe.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter sales of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Enjaymo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8482;, the first approved treatment for patients with cold agglutinin disease were &#8364;16 million mainly generated in the U.S. and Japan. </font></div><div id="i2456b270d3a64714a6867e4852c38438_513"></div><div style="margin-top:15pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">General Medicines</font><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Core assets</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lovenox</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">323&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-11.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Toujeo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">289&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plavix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-6.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thymoglobulin</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Praluent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+42.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multaq</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-6.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rezurock</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font></div></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+56.1&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">core assets</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales increased 1.6% (to &#8364;1,617 million), mainly driven by double-digit growth of Praluent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, Rezurock</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">,</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thymoglobulin</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Soliqua</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, offset by lower sales of Lovenox</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and Plavix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;.</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lovenox</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales decreased 11.9% to &#8364;323 million, reflecting lower COVID-19 related demand compared to the first quarter of 2022, and increased competition from </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">biosimilars. </font></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:107%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:107%">Toujeo</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> sales increased 4.4% to &#8364;289 million, driven by Europe and the U.S. In the Rest of the World region performance reflected lower sales in China mainly due to a high base in the first quarter of 2022 ahead of the VBP implementation.  </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Plavix</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sales were down 6.5% in the first quarter at &#8364;236 million, due to a mandatory price cut in Japan in April 2022. In China, sales were down 1.6% to &#8364;117 million, reflecting the impact from provincial VBP renewal. </font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7.8pt;font-weight:400;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:115%">Sanofi has prioritized core assets in its General Medicines portfolio with differentiated and&#47;or established profiles that have significant opportunity for growth in key markets. </font></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  4                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Praluent</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> first-quarter sales were &#8364;98 million, up 42.0%,</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">driven by strong performance in Europe and China.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rezurock</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;67 million, up 56.1% in the first quarter driven by new patient adoption and improved adherence. Since launch more than 1,580 patients have been treated with Rezurock</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">.</font></div><div style="margin-bottom:6pt;margin-top:9pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Non-core assets </font></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter, </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">non-core assets sales </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">decreased 20.5% to &#8364;1,520 million mainly reflecting divestments (-2.2 ppt) and lower sales of Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales were &#8364;447 million, down 32.6% in the first quarter. In the U.S., sales decreased 39.4%, impacted by the continued erosion of the basal insulin market combined with lower average net price. In Rest of the World region, sales were down 34.8% reflecting lower price due to the insulin VBP implementation in China in addition to a quarterly high base for comparison.</font></div><div id="i2456b270d3a64714a6867e4852c38438_70"></div><div style="margin-top:15pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vaccines</font><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Change <br>at CER</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Polio&#47;Pertussis&#47;Hib vaccines</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Meningitis, Travel and endemic vaccines </font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+16.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:174%">Booster vaccines </font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+11.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Influenza vaccines</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+6.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+781.8%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Vaccines</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> sales increased 15.2% (to &#8364;1,167 million) notably reflecting contractual sales of VidPrevtyn</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Beta (&#8364;167 million), a recombinant COVID-19 booster vaccine in Europe, recorded in &#8220;others&#8221;. In addition, Booster and Travel vaccines product sales continued to recover following the COVID-19 related slowdown in the years 2020 and 2021, leading to double-digit growth of the respective franchises. The sales of Japanese Encephalitis vaccine (recorded in Traveler &#38; Endemic vaccines and divested in the fourth quarter of 2022) were &#8364;19 million in the first quarter of 2022. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter, </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Polio&#47;Pertussis&#47;Hib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (PPH) vaccines sales decreased 11.3% to &#8364;537 million mainly reflecting lower sales in the Rest of the World region due to product discontinuation and a high base for comparison for injectable polio vaccine in the first quarter of 2022 due to favorable phasing. In the U.S. Vaxelis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">continues to capture market share progressively replacing pentavalent vaccines (including Pentacel</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">) in the primary series of infant immunization. As a reminder, Vaxelis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in-market sales are not consolidated and the profits are shared equally between Sanofi and Merck &#38; Co.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Meningitis, Travel and endemic</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> vaccines sales grew 16.7% (to &#8364;249 million) driven by sales of meningitis vaccines in the Rest of the World region and the continued recovery of Travel-related vaccines that are reaching almost their pre-COVID levels. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Booster</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> vaccines sales increased 11.9% in the first quarter to &#8364;124 million, driven by the U.S. and Europe.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_76"></div><div style="text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Biopharma business operating income</font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter, </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">business operating income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (BOI) of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Biopharma</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 12.2% to &#8364;2,789 million (up 12.6% at CER) driven by gross profit improvement and higher capital gains than the first quarter of 2022, partly offset by higher SG&#38;A costs due to product launch costs in Specialty Care. The ratio of BOI to net sales increased by 2.1 ppts to 32.0% (32.2% at CER). </font></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:justify"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_100"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">R&#38;D update at the end of the first quarter 2023</font></div><div style="margin-top:6pt;padding-left:9pt;padding-right:4.5pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:115%">Regulatory update</font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:115%"> </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">The U.S. Food and Drug Administration (FDA) approved </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ALTUVIIIO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(efanesoctocog alfa), a first-in-class, high-sustained factor VIII replacement therapy, indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as perioperative management (surgery) for adults and children with hemophilia A. ALTUVIIIO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is the first and only hemophilia A treatment that delivers normal to near-normal factor activity levels (over 40%) for most of the week with once-weekly dosing, and significantly reduces bleeds compared to prior factor VIII prophylaxis.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The approval is based on data from the pivotal XTEND-1 Phase 3 study in adults and adolescents with hemophilia A recently published in the New England Journal of Medicine.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  5                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the XTEND-Kids Phase 3 pivotal study evaluating the safety, efficacy and pharmacokinetics of ALTUVIIIO</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> as once-weekly prophylaxis in previously treated children younger than 12 years with severe hemophilia A met its primary endpoint of safety, with no FVIII inhibitors detected.</font></div><div style="margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:8.05pt">The FDA accepted for review the supplemental Biologics License Application (sBLA) for </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%">(dupilumab) to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU), not adequately controlled with the current standard of care (H1 antihistamine treatment), with a PDUFA date of October 22, 2023. An application was also submitted to the Pharmaceuticals and Medical Devices Agency (PDMA) in Japan.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">The European Commission (EC) approved </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy. With this approval, Dupixent&#174; is the first and only targeted medicine indicated to treat these young children in Europe and the U.S. </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">The EC expanded the marketing authorization for </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, in the European Union to treat eosinophilic esophagitis (EoE) in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. With this approval, Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> is the first and only targeted medicine specifically indicated to treat EoE in Europe and the U.S.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Portfolio update</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 3&#58;</font></div><div style="margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:110%;padding-left:8.52pt">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:110%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%">demonstrated a clinically meaningful and highly significant reduction (30%) in moderate or severe acute exacerbations of COPD (rapid and acute worsening of respiratory symptoms) in the pivotal BOREAS study. Significant improvements in lung function, quality of life and COPD respiratory symptoms. Efficacy and safety results from this trial will be presented at The American Thoracic Society (ATS) Conference. The second, replicate Phase 3 trial of Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:110%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:110%"> in COPD (NOTUS) is ongoing with data expected in 2024.</font></div><div style="margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A Phase 3 study evaluating Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Chronic Inducible Cold Urticaria (LIBERTY-CINDU) did not meet the required efficacy endpoints to continue this program.</font></div><div style="margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> programs in Allergic Fungal Rhinosinusitis (AFRS) and Chronic Rhinosinusitis without Nasal Polyps (CRsNP) will be discontinued due to portfolio prioritization. The ongoing studies will be amended and completed.</font></div><div style="margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">New data for </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">tolebrutinib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> from a collaborative research and development partnership with the National Institute of Neurological Disorders and Stroke (NINDS) showed the significant impact on neuroinflammatory biomarkers in the central nervous system associated with disease progression and addressing disability accumulation, which is a significant unmet need in multiple sclerosis. The data were presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2023.</font></div><div style="margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">Results from the ATLAS-INH and ATLAS A&#47;B studies evaluating the efficacy and safety of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">fitusiran</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, an investigational siRNA therapy for the prophylactic treatment of adults and adolescents with hemophilia A or B, reinforcing the potential of this investigational therapy to transform the current standard of care and address unmet needs for all types of hemophilia, regardless of inhibitor status, were published respectively in The Lancet and The Lancet Haematology.</font></div><div style="margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">Long-term extension data from the Phase 3 COMET study showing sustained treatment effect of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Nexviazyme</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> over nearly three years in late-onset Pompe disease patients, who were treatment-na&#239;ve as well as those who switched from long-time standard of care alglucosidase alfa, were presented at WORLDSymposium</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">TM</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 2&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">The study assessing the efficacy, tolerability, and safety of the RIPK1 inhibitor </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SAR443820</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in patients with multiple sclerosis enrolled its first participants.</font></div><div style="margin-top:3pt;padding-left:22.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">The development of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">atuzabrutinib</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, a topical BTKi, was discontinued based on results of the study evaluating the compound in patients with mild to moderate atopic dermatitis, due to efficacy and sub-optimal pharmacokinetics.</font></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">The study evaluating the safety, pharmacokinetics, and efficacy of subcutaneous</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> Sarclisa</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in adults With Warm Autoimmune Hemolytic Anemia (wAIHA), was discontinued based on the preliminary results and portfolio prioritization.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">Studies evaluating the efficacy and safety of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dupixent</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in Ulcerative Colitis (UC, NCT05731128) and Eosinophilic Gastritis (EG, NCT05831176) have been initiated.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Phase 1&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:22.5pt;padding-right:4.5pt;text-align:justify;text-indent:-13.5pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:8.05pt">The study evaluating the safety, tolerability, and pharmacokinetics of </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SAR444419</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (anti-TNFa&#47;IL-6 Nanobody</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> VHH) in healthy subjects, was discontinued based on the benefit&#47;risk assessment.</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  6                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Organizational update</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 13</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, Sanofi announced the departure of John Reed, former Global Head of R&#38;D. An internal and external search to identify the successor is ongoing. Dietmar Berger, Chief Medical Officer and Global Head of Development has taken on the role of Global Head of R&#38;D ad interim.</font></div><div style="margin-top:3pt;padding-right:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">An update of the R&#38;D pipeline as of March 31, 2023, is available on our website</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#58; </font><font style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;www.sanofi.com&#47;en&#47;science-and-innovation&#47;research-and-development</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_82"></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Consumer Healthcare </font></div><div style="margin-bottom:1pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">Change </font></div><div style="text-align:right"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">at CER</font></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Allergy</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cough &#38; Cold </font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+22.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pain Care</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+4.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Digestive Wellness</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Physical and Mental Wellness</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">-2.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Personal Care</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">+12.3&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter, </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Consumer Healthcare</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (CHC) sales increased 11.2% to &#8364;1,495 million driven by growth in all regions and also includes approximately &#8364;40 million of positive phasing effect of inventory in trade. This global performance includes a positive price effect of 6.6 ppts. The divestments of non-core products had a negative impact of 1.5 ppt mainly impacting the non-core&#47;others category. As a result, the CHC organic sales growth was 12.7% in the first quarter. </font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> U.S.</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, first-quarter CHC sales increased 14.5% to &#8364;371 million driven by double-digit growth of Digestive Wellness Allergy and Personal Care categories and included a positive phasing effect of inventory in trade. </font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Europe</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, first-quarter CHC sales increased 11.6% to &#8364;448 million mainly reflecting double-digit growth of Cough &#38; Cold, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:115%">Digestive Wellness and Allergy categories</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Rest of World</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, first-quarter CHC sales increased 9.2% to &#8364;676 million, supported by double-digit growth of the Digestive, Pain Care and Allergy categories and included a positive phasing effect of inventory in trade.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_88"></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">CHC business operating income</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with the progress of the CHC stand-alone setup within Sanofi, the CHC segment reporting now reflects the fully integrated R&#38;D, manufacturing and supply activities as well as related Global Support Functions.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter, </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">business operating income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (BOI) of CHC increased 0.6% (up 2.4% at CER) to &#8364;534 million reflecting strong sales growth in part driven by stock in trade stockpile phasing. This was offset by lower capital gains related to divestments versus the first quarter of 2022, increased R&#38;D expenses (up 29.3%) linked to phasing of projects and higher stand-alone costs.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ratio of BOI to net sales decreased 3.5 ppts to 35.7% (36.1% at CER) versus the first quarter of 2022. </font></div><div style="text-align:justify"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  7                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_106"></div><div style="margin-top:9pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Corporate Social Responsibility update at the end of the first quarter 2023</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:102%">Access to healthcare</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Sanofi partnering with the Ghana Ministry of Health to improve affordable access to diabetes care </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In order to offer solutions adapted to local needs, Sanofi is piloting a new business model in selected low-and middle-income countries to increase access to insulin. Countries are chosen based on their governments committing to tackle non-communicable diseases (NCDs)&#59; the priority of diabetes on their healthcare agenda&#59; and government interest in incorporating analog insulins, recently included in the WHO EML (WHO Model List of Essential Medicines). </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These innovative partnerships with healthcare authorities will provide the blueprint to scale up the program within the pilot country, as well as to expand to other countries over the next three to five years. By rolling out this new business model, we are aiming to improve the lives of 190,000 people living with either Type 1 or Type 2 diabetes within the next 5 years.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The recently signed Ghana-Sanofi partnership delivered through Sanofi&#8217;s General Medicines Business Unit and in close collaboration with the Ministry of Health of Ghana and other stakeholders and partners includes high-quality analogue insulins at affordable price (included in WHO EML now), patient disease awareness, HCP training, regional care centers, and digital solutions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Sanofi capping its insulin to a $35 out-of-pocket costs in the U.S. </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi has decided that it will cut the list price of Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (insulin glargine injection), its most widely prescribed insulin in the U.S., by 78%. The company will also establish a $35 cap on out-of-pocket costs for Lantus</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for all patients with commercial insurance, underscoring its longstanding commitment to offer affordable access to medicines. These steps will become effective January 1st, 2024.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sanofi will continue to provide different programs to ensure access and affordability to diabetes patients depending on their coverage situations and will continue to monitor policy and market changes. Our suite of innovative programs includes&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.33pt">100% of commercially insured people are eligible for Sanofi&#8217;s copay assistance programs, regardless of income or insurance plan design, which, in 2022 limited out-of-pocket expenses for a majority of participating patients to $15 or less for their diabetes medicines for a 30-day supply.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.33pt">100% of uninsured people are eligible for the Insulins Valyou Savings Program &#8211; regardless of income level &#8211; enabling them to buy one or multiple Sanofi insulins at $35 for a 30-day supply. </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8211;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.33pt">We also provide free medications to qualified low- and middle-income patients through the Sanofi Patient Connection program. Some people facing an unexpected financial hardship may be eligible for a one-time, immediate month&#8217;s supply of their Sanofi medicine as they wait for their application to be processed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Learn more about Sanofi&#8217;s transparent approach to pricing in the U.S. in the company 2023 U.S. Pricing Principles Report.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Launch of &#8220;A Million Conversations&#8221;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A Million Conversations is Sanofi&#8217;s global initiative to rebuild trust in healthcare with the underrepresented, especially with Black and ethnic minority groups, women, people with disabilities, and LGBTQ+ communities. Sanofi aims to help build the next generation of diverse healthcare leaders.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In partnership with leading higher education institutions across the world, the Sanofi NextGen Scholarship will identify up to 100 new students from marginalized communities each year. Selected Scholars will be awarded funding to cover partial university fees and living costs. And they will receive development support, mentorship, internship opportunities, and potential employment once they graduate.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:102%">Environment</font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Net Zero emissions by 2045 and updated scope 3 targets validated by Science Based Targets Initiative (SBTi)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sanofi announced in Q4 2022 it accelerates its efforts to address climate change and has built an ambitious path to achieve Net Zero emissions across all operations (scope 1 &#38; 2) and the entire value chain (scope 3) by 2045. This target has been vetted by SBTi as well our updated scope 3 reduction target of achieving -30% GHG emissions by 2030 vs our 2019 baseline. </font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  8                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net Zero emissions means achieving a scale of value chain emissions reductions consistent with the depth for abatement at the point of reaching global net-zero in 1.5&#176;C pathways and neutralizing the impact of any residual emissions by permanently removing an equivalent volume of CO2e.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Sanofi inaugurated its first self-consumption photovoltaic park on its Montpellier site in France</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sanofi and EDF ENR inaugurated a new 3.3-hectare photovoltaic park at Sanofi's research and development site in Montpellier. The park is producing electricity that is fully self-consumed by the site since February 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">With an annual electricity production of 5,490 MWh, i.e. the equivalent of the consumption of a city of 4,000 people, this photovoltaic park, which will be supplemented by a ground-based power station in 2024 covers 17.5% of the annual electricity needs from the site. The rest of these needs are covered by a supply of 100% renewable electricity.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This project is part of our larger ambition to use 100% renewable electricity by 2030 worldwide. Beyond the Montpellier site, other large-scale solar power plant installations are planned for the Aramon site in July 2023, the Ambar&#232;s site in 2024 and the Sisteron site in the near future. Similar plants are already in operation at the sites of Virginia in Australia, Goa in India and Scoppito in Italy.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:102%">ESG ratings</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Here are the latest Sanofi ESG rankings&#58; </font></div><div><img alt="ratingagenciesq123a.jpg" src="ratingagenciesq123a.jpg" style="height:289px;margin-bottom:5pt;vertical-align:text-bottom;width:716px"></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  9                   </font></div></div></div><div id="i2456b270d3a64714a6867e4852c38438_109"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">First-quarter 2023 financial results</font></div><div style="margin-top:3pt"><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Business Net Income</font><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:7.8pt;font-weight:700;line-height:115%;position:relative;top:-4.2pt;vertical-align:baseline">3</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2023, Sanofi generated</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> net sales</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of &#8364;10,222 million, an increase of 5.7% (up 5.5% at CER). </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">other revenues</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 69.1% (up 61.7% at CER) to &#8364;641 million, including increased VaxServe sales of non-Sanofi products of &#8364;390 million (up 30.8% at CER), COVID-19 vaccine related revenues (&#8364;62 million) and favorable phasing. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Gross Profit</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 8.5% (up 8.1% at CER) to &#8364;7,784 million. The gross margin ratio increased 1.9 ppt to 76.1% versus the same period of 2022, mainly reflecting improvement of the Biopharma gross margin ratio (which increased from 75.2% to 77.7%) driven by favorable product mix and the deconsolidation of EUROAPI. CHC gross margin ratio increased 0.4 ppt to 67.0%. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and Development </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(R&#38;D)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expenses were up 5.0% (up 3.9% at CER) to &#8364;1,563 million in the first quarter, mainly reflecting increased expenses in vaccines, especially for the mRNA Center of Excellence. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">selling general and administrative expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (SG&#38;A) increased 9.6% to &#8364;2,607 million. At CER, SG&#38;A expenses were up 8,7%, reflecting increased commercial investments and launch costs in Specialty Care and further investments in CHC. In the first quarter, the ratio of SG&#38;A to sales increased 0.9 ppt to 25.5% compared to the prior year. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">operating expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;4,170 million (up 7.8% and 6.9% at CER).</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">other current operating income net of expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> was &#8364;-304 million versus &#8364;-265 million in the first quarter of 2022. Other current operating income net of expenses included an expense of &#8364;674 million (versus an expense of &#8364;477 million in the first quarter of 2022) corresponding to the share of profit to Regeneron of the monoclonal antibodies Alliance, additional share of profit paid by Regeneron towards development costs (which increased from 10% to 20% from April 1, </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9.96pt;font-weight:400;line-height:115%">2022)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the reimbursement of commercialization-related expenses incurred by Regeneron. In the first quarter, this line also included &#8364;307 million of net capital gains related to portfolio streamlining compared to &#8364;232 million in the same period of 2022. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The first-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">share of profit from associates </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">was &#8364;33 million versus &#8364;30 million in the same periods of 2022 and included the share of U.S. profit related to Vaxelis</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">business operating income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (BOI) increased 8.7% to &#8364;3,333 million. At CER, BOI increased 9.3%. The ratio of BOI to net sales increased 0.9 ppt to 32.6%. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Net financial expenses</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> were &#8364;-7 million in the first quarter, versus &#8364;-78 million in the same period of 2022, reflecting increased short-term interest rate on the cash &#38; cash equivalents. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">effective tax rate</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> was stable at 19.0% versus the same period of 2022. Sanofi expects its effective tax rate to be around 19% in 2023.</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">First-quarter </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">business net income</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> increased 11.3% to &#8364;2,699 million and increased 11.9% at CER. The ratio of business net income to net sales increased 1.3 ppts to 26.4% versus the first quarter of 2022. </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2023,</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> business earnings per share</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:700;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(EPS) was &#8364;2.16, up 11.3% on a reported basis (up 11.9% at CER). The average number of shares outstanding was 1,249.3 million versus 1,249.2 million in the first quarter of 2022.</font></div><div id="i2456b270d3a64714a6867e4852c38438_112"></div><div style="margin-top:6pt;text-align:justify"><font><br></font></div><div><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Reconciliation of IFRS net income reported to business net income (see Appendix 4) </font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2023, the IFRS net income was &#8364;1,995 million</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:115%">. </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The main items excluded from the business net income were&#58;</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">An amortization charge of &#8364;489 million related to fair value remeasurement on intangible assets of acquired companies (primarily Bioverativ&#58; &#8364;152 million, Genzyme&#58; &#8364;107 million, Boehringer Ingelheim CHC business&#58; &#8364;48 million, Ablynx&#58; &#8364;42 million and Kadmon &#8364;39 million) and to acquired intangible assets (licenses&#47;products&#58; &#8364;30 million). These items have no cash impact on the Company.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">Restructuring costs and similar items of &#8364;240 million related to streamlining initiatives.</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">S</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">ee Appendix 3 for 2023 first-quarter consolidated income statement&#59; see Appendix 7 for definitions of financial indicators, and Appendix 4 for reconciliation of IFRS net income reported to business net income</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">. </font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  10                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">Other gains and losses, and litigation charge of &#8364;88 million, mainly including costs related to a settlement of a Bioverativ shareholders litigation.</font></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">A &#8364;168 million tax effect arising from the items listed above, mainly comprising &#8364;94 million of deferred taxes generated by amortization and impairments of intangible assets and</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#8364;49 </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">million associated with restructuring costs and similar items (see Appendix 4). </font></div><div style="margin-top:3pt;text-align:justify"><font><br></font></div><div><font style="color:#23004c;font-family:'Verdana',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Capital Allocation</font></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2023, free cash flow before restructuring, acquisitions and disposals decreased by 12.2% to &#8364;1,754 million, after net changes in working capital </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8364;-627 milli</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on) and capital expenditures (&#8364;-447 million). After acquisitions</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8364;-292 million</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, proceeds from disposals</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (&#8364;408 million) and payments related to restructuring and similar items (-&#8364;333 million), </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">free cash flow</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> decreased 10.0%</font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to &#8364;1,537 million. Net debt decreased from &#8364;6,437 million on December 31, 2022 to &#8364;5,305 million on March 31, 2023 (amount </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">net of &#8364;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12,064 </font><font style="background-color:#ffffff;color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">milli</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on cash and cash equivalents).</font></div><div style="border-bottom:1pt solid black;margin-bottom:5pt;margin-top:10pt;width:150pt"></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Not exceeding &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">non-GAAP financial measure (definition in Appendix 7).</font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  11                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_121"></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="background-color:#ffffff;color:#404040;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:112%">This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words &#8220;expects&#8221;, &#8220;anticipates&#8221;, &#8220;believes&#8221;, &#8220;intends&#8221;, &#8220;estimates&#8221;, &#8220;plans&#8221; and similar expressions. Although Sanofi&#8217;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#8217;s ability to benefit from external growth opportunities, to complete related transactions and&#47;or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward-Looking Statements&#8221; in Sanofi&#8217;s annual report on Form 20-F for the year ended December 31, 2022. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_124"></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:16pt;font-style:italic;font-weight:400;line-height:115%">Appendices</font></div><div><font><br></font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:12.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i2456b270d3a64714a6867e4852c38438_127" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix&#160;1&#58;</a>&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-quarter 2023<a href="#i2456b270d3a64714a6867e4852c38438_127" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> sales by GBU, franchise, geographic region and product</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i2456b270d3a64714a6867e4852c38438_133" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 2&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-quarter<a href="#i2456b270d3a64714a6867e4852c38438_133" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> </a><a href="#i2456b270d3a64714a6867e4852c38438_133" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">202</a><a href="#i2456b270d3a64714a6867e4852c38438_133" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">3</a><a href="#i2456b270d3a64714a6867e4852c38438_133" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> business net income statement</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i2456b270d3a64714a6867e4852c38438_139" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 3&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First-quarter <a href="#i2456b270d3a64714a6867e4852c38438_139" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">202</a><a href="#i2456b270d3a64714a6867e4852c38438_139" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">3</a><a href="#i2456b270d3a64714a6867e4852c38438_139" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none"> consolidated income statement</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i2456b270d3a64714a6867e4852c38438_142" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix 4&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i2456b270d3a64714a6867e4852c38438_142" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Reconciliation of IFRS net income reported to business net income</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><a href="#i2456b270d3a64714a6867e4852c38438_145" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:none">Appendix 5&#58;</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%"><a href="#i2456b270d3a64714a6867e4852c38438_145" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:174%;text-decoration:none">Change in net debt</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 6&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency sensitivity</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i2456b270d3a64714a6867e4852c38438_160" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Appendix </a>7&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a href="#i2456b270d3a64714a6867e4852c38438_160" style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none">Definitions of non-GAAP financial indicators</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Appendix 8&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSR Dashboards</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><font><br></font></div><div style="text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Media Relations</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Sandrine Guendoul </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 25 09 14 25 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">sandrine.guendoul&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Nicolas Obrist </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 77 21 27 55 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">nicolas.obrist&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Victor Rouault </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 70 93 71 40 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">victor.rouault&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Sally Bain </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 1 617 834 6026 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">sally.bain&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Evan Berland</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> &#124; +1 215 432 0234 &#124; </font><font style="color:#5400b8;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">evan.berland&#64;sanofi.com</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Investor Relations</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Eva Schaefer-Jansen </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 7 86 80 56 39 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">eva.schaefer-jansen&#64;sanofi.com </font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Arnaud Del&#233;pine </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 73 69 36 93 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">arnaud.delepine&#64;sanofi.com </font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Corentine Driancourt </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 6 40 56 92 21 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">corentine.driancourt&#64;sanofi.com  </font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Felix Lauscher </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 1 908 612 7239 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">felix.lauscher&#64;sanofi.com </font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Nathalie Pham </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 33 7 85 93 30 17 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">nathalie.pham&#64;sanofi.com</font></div><div style="margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Tarik Elgoutni</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#124; + 1 617 710 3587 &#124; </font><font style="color:#7a00e6;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Tarik.Elgoutni&#64;sanofi.com </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  12                   </font></div></div></div><div id="i2456b270d3a64714a6867e4852c38438_127"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 1&#58; 2023 first-quarter net sales by GBU, franchise, geographic region and product</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:21.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Q1 2023 (&#8364; million)</font></td><td colspan="3" style="background-color:#23004c;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total Sales</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% reported</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">United States</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Europe</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="background-color:#23004c;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Rest of the world</font></td><td colspan="3" style="background-color:#23004c;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">% CER</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Dupixent</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2,316</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+39.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+43.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1,759</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+43.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">277</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+32.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">280</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+27.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aubagio</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">419</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-16.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-14.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">273</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-20.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">120</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">26</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Myozyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">228</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-3.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-3.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">69</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-19.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">95</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+32.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Fabrazyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">246</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+11.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+11.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">123</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">62</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+8.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">61</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+14.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cerezyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">196</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+26.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">47</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">60</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">89</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+73.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Eloctate</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">118</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-15.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-14.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">85</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+16.7&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Alprolix</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">125</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+15.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">107</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+10.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Nexviazyme&#47;Nexviadzyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">81</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+163.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+170.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">56</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+107.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1600.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+166.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Jevtana</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">79</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-21.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-19.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">55</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-22.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-63.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">20</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+5.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Sarclisa</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">87</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+33.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+33.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">37</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+40.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+27.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">22</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+33.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Kevzara</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-23.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-23.2&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-32.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">27</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-3.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-29.4&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cerdelga</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">73</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+7.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+9.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">40</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">29</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+7.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aldurazyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">78</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+14.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+13.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+30.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">21</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">39</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+28.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cablivi</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">58</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+23.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+26.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">27</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+17.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+300.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Fasturtec</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">45</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">27</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Enjaymo</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">16</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1500.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1500.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">9</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+700.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Xenpozyme</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1700.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1700.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+700.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Others</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">31</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-61.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-62.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-54.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-85.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">20</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-34.4&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Specialty Care</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,288</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+18.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+20.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,785</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+20.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">795</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+6.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">708</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+25.3</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Toujeo</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">289</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+5.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">65</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+6.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">109</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+5.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">115</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Lovenox</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">323</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-11.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-14.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-20.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">174</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-4.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">145</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-19.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Plavix</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">236</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-9.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">2</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-33.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">24</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-7.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">210</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Thymoglobulin</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">109</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">69</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+17.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">10</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-3.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Multaq</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">84</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-3.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">76</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-40.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Praluent</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">98</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+42.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+42.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">71</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+34.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">28</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+75.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Rezurock</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">67</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+56.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+63.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">66</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+53.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Mozobil</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">67</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+13.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+15.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">42</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+29.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">17</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+20.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-33.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Soliqua&#47;iGlarLixi</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">63</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+15.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">32</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+3.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">8</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+40.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Others core assets</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">281</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+1.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-15.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">99</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+4.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">146</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+3.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Core Assets</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,617</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+1.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+1.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">391</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+9.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">516</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+4.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">710</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-3.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Lantus</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">447</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-32.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-33.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">132</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-39.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">96</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">219</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-34.8&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Aprovel</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">110</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-12.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-12.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">20</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-4.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">89</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Others non-core assets</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">963</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-14.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-17.1&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">64</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-33.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">256</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-13.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">643</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-12.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-Core Assets</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1,520</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-20.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-22.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">197</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-37.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">372</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-13.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">951</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-18.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Industrial Sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">135</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-27.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-25.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">1</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-90.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">127</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">-26.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">7</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">+75.0</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;General Medicines</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,272</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-11.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-12.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">589</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-13.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,015</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-7.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,668</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-12.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Influenza vaccines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">63</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+6.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-4.5&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">6</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-50.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">5</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">52</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Polio&#47;Pertussis&#47;Hib vaccines </font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">537</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-11.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-12.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">129</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-0.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">71</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-7.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">337</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-15.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Meningitis, Travel and endemic vaccines</font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">249</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+16.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.6&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">101</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-2.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">34</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+78.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">114</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+23.9&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Booster vaccines </font></div></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">124</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+11.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+13.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">67</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+20.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">37</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+19.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">20</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-16.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">RSV</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Vaccines</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,167</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+15.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+14.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">324</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+1.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">318</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">+139.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">525</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-6.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">8,727</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+4.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+4.9</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,698</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+11.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,128</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+7.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,901</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-4.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Allergy</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">276</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+17.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+17.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">162</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">23</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+41.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">91</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+10.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Cough and Cold</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">145</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+22.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+19.8&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">0.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">94</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+43.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">51</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-3.6&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Pain Care</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">306</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+4.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+3.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">45</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-6.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">138</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+2.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">123</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.3&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Digestive Wellness</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">425</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+21.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+18.7&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">41</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+34.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">144</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+14.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">240</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+24.4&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Physical and Mental Wellness</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">154</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-2.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-1.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+8.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-10.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">105</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-1.0&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Personal Care</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">150</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+12.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+15.4&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">114</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+14.6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-100.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">36</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+9.1&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">Non-Core &#47; Others</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">39</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-32.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-33.9&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(4)</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">+25.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">13</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-26.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">-29.5&#160;</font></td><td style="border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Healthcare</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,495</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+11.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+10.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">371</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+14.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">448</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+11.6</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">676</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+9.2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-right:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-right:2pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-left:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,222</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+5.5</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+5.7</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,069</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+11.8</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,576</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">+8.4</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,577</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">-2.1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:2pt solid #000000;border-right:2pt solid #000000;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  13                   </font></div></div></div><div id="i2456b270d3a64714a6867e4852c38438_133"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">Appendix 2&#58; Business net income statement</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.860%"><tr><td style="width:1.0%"></td><td style="width:17.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.679%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">First quarter 2023</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Biopharma</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consumer Healthcare</font></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Other</font></div></td><td colspan="9" style="background-color:#23004c;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Group</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q1 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q1 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q1 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:120%">Q1 2022</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">Change</font></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">8,727</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">8,320</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">4.9%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,495</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,354</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">10.4%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">10,222</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">9,674</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">5.7%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">626</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">365</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">71.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">15</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">14</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">7.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">&#8212;%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">641</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">379</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">69.1%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of Sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,569)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,428)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">5.8%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(508)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(466)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">9.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">16</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-112.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3,079)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,878)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">7.0%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(29.4)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(29.2)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(34.0)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(34.4)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(30.1)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(29.7)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Profit</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6,784</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">6,257</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">8.4%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1,002</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">902</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">11.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">(2)</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">16</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-112.5%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">7,784</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">7,175</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">8.5%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">77.7%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">75.2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">67.0%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">66.6%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">76.1%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">74.2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,510)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,451)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">4.1%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(53)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(41)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">29.3%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-100.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,563)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,489)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">5.0%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(17.3)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(17.4)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(3.5)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(3.0)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(15.3)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(15.4)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,124)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1,936)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">9.7%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(484)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(447)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">8.3%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">-75.0%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,607)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(2,379)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">9.6%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(24.3)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(23.3)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(32.4)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(33.0)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(25.5)%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">(24.6)%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other current operating income&#47;expenses</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(386)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(413)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">71</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">123</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">11</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">25</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(304)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(265)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share of profit&#47;loss of associates* and joint ventures</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">33</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">30</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net income attributable to non controlling interests</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(1)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(5)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(6)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">&#8212;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(10)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business operating income</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,789</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,486</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">12.2%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">534</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">531</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">0.6%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">10</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">48</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">-79.2%</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">3,333</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">3,065</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">8.7%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">32.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">29.9%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">35.7%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">39.2%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">32.6%</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">31.7%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Financial income and expenses</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(7)</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(78)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Income tax expenses</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(627)</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(563)</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Tax rate**</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">19.0%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:400;line-height:100%">19.0%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="9" style="background-color:#f4f2f6;padding:0 1pt"></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,699</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2,424</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">11.3%</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">As % of net sales</font></td><td colspan="9" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">26.4%</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">25.1%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="18" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Business earnings &#47; share(in euros)***</font></td><td colspan="3" style="background-color:#f4f2f6;border-left:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">2.16</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-weight:700;line-height:100%">1.94</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6pt;font-style:italic;font-weight:700;line-height:100%">11.3%</font></td></tr></table></div><div style="margin-bottom:3pt;margin-top:1pt"><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">* Net of tax.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">** Determined on the basis of Business income before tax, associates, and non-controlling interests.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">*** Based on an average number of shares outstanding of 1,249.3 million in the first quarter of 2023 and 1,249.2 million in the first quarter of 2022.</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-indent:8.99pt"><font><br></font></div><div style="text-indent:8.99pt"><font><br></font></div><div style="text-indent:8.99pt"><font><br></font></div><div style="text-indent:8.99pt"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  14                   </font></div></div></div><div id="i2456b270d3a64714a6867e4852c38438_139"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 3&#58; Consolidated income statements</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:77.636%"><tr><td style="width:1.0%"></td><td style="width:70.123%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.288%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.289%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,222</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,674</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">641&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,079)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,880)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross profit</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,784</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7,173</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,563)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and general expenses</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,607)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,379)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">436&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other operating expenses</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(740)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(655)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(489)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(449)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment of intangible assets</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(240)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(175)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:10pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other gains and losses, and litigation</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,463</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,397</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial expenses</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income before tax and associates and joint ventures</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,456</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,319</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(459)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(332)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share of profit&#47;(loss) of associates and joint ventures</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,009</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,017</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to non-controlling interests</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,995</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,009</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Average number of shares outstanding (million)</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,249.3&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,249.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">IFRS Earnings per share (in euros)</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  15                   </font></div></div></div><div id="i2456b270d3a64714a6867e4852c38438_142"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 4&#58; Reconciliation of Net income attributable to equity holders of Sanofi to Business net income</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.798%"><tr><td style="width:1.0%"></td><td style="width:68.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Q1 2022</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income attributable to equity holders of Sanofi</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,995</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,009</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Amortization of intangible assets </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">449&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Impairment of intangible assets </font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expenses arising from the impact of acquisitions on inventories</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other gains and losses, and litigation </font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax effect of the items listed above&#58;</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(168)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(232)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Amortization and impairment of intangible assets</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(94)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(96)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Fair value remeasurement of contingent consideration</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(5)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(7)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Restructuring costs and similar items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(49)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(46)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other tax effects</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(20)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(83)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,699</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,424</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">IFRS earnings per share </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:700;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in euros)</font></div></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.60</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.61</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.21pt">Of which related to amortization expense generated by the remeasurement of intangible assets as part of business combinations&#58; &#8364;459 million in the first quarter of 2023 and &#8364;420 million in the first quarter of 2022.</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:5.66pt">Based on an average number of shares outstanding of 1,249.3 million in the first quarter of 2023 and 1,249.2 million in the first quarter of 2022.</font></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:3pt;text-indent:36pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="margin-top:3pt"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  16                   </font></div></div></div><div id="i2456b270d3a64714a6867e4852c38438_145"></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 5&#58; Change in net debt</font></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.766%"><tr><td style="width:1.0%"></td><td style="width:70.039%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.330%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.331%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;Q1 2022</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business net income</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,699</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,424</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation &#38; amortization &#38; impairment of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(241)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating cash flow</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,828</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,822</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Working Capital</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(627)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(468)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions of property, plant and equipment and software</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(447)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(356)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free cash flow before restructuring, acquisitions and disposals</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,754</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,998</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of intangibles assets, investments and other long-term financial assets </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(292)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(277)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring costs and similar items paid</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(333)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(361)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from disposals of property, plant and equipment, intangible assets and other non-current assets net of taxes</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;(1)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free cash flow</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,537</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,707</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Acquisitions of investments in consolidated undertakings including</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:120%">assumed debt </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(823)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of Sanofi shares</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisition of treasury shares</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(363)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(360)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other items</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change in net debt</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,132</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">551</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beginning of period</font></td><td colspan="2" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,437</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,983</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-top:2pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Closing of net debt</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,305</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,432</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.21pt">Free cash flow includes investments and divestments not exceeding a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%;padding-left:7.21pt">Includes transactions that are above a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  17                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:3pt;margin-top:3pt"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_157"></div><div style="margin-bottom:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 6&#58; Currency sensitivity</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023 business EPS currency sensitivity</font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currency</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Variation</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Business EPS Sensitivity</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Dollar</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.05 USD&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.17</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japanese Yen</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+5 JPY&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-EUR 0.02</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chinese Yuan</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.2 CNY&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.03</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazilian Real</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+0.4 BRL&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.02</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Ruble</font></td><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+10 RUB&#47;EUR</font></td><td colspan="3" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;-EUR 0.02</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:87%">Currency exposure on Q1 2023 sales</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:87%"> </font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Currency</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2023</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">US $</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Euro &#8364;</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chinese Yuan</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japanese Yen</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazilian Real</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian ruble</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexican pesos</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian $</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canadian $</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">British Pound</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Others</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17.1&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:80%">Currency average rates </font></div><div style="margin-bottom:4pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:0 1pt"></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2022</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Q1 2023</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Change</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;$</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.123&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.073&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">-4.4&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Yen</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130.473&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142.049&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+8.9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Yuan</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.135&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.349&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">+3.0&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Real</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.883&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.575&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">-5.2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8364;&#47;Ruble</font></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.949&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.351&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="2" style="border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">-20.0&#160;</font></td><td style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:4pt;margin-top:6pt"><font><br></font></div><div style="margin-bottom:4pt;margin-top:6pt"><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  18                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div style="margin-bottom:4pt;margin-top:6pt"><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_160"></div><div style="margin-bottom:3pt;margin-top:6pt"><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%">Appendix 7&#58; Definitions of non-GAAP financial indicators</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Company sales at constant exchange rates (CER)</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we refer to changes in our net sales &#8220;at constant exchange rates&#8221; (CER), this means that we exclude the effect of changes in exchange rates.</font></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We eliminate the effect of exchange rates by recalculating net sales for the relevant period at the exchange rates used for the previous period.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Reconciliation of net sales to Company sales at constant exchange rates for the first quarter 2023</font></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8364; million</font></td><td colspan="3" style="background-color:#23004c;padding:2px 1pt;text-align:right;vertical-align:middle"><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Q1  2023</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net sales</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,222</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rates</font></td><td colspan="2" style="background-color:#f4f2f6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#f4f2f6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #525ca3;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Company sales at constant exchange rates</font></td><td colspan="2" style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,206</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#f4f2f6;border-bottom:0.5pt solid #525ca3;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Business net income</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanofi publishes a key non-GAAP indicator. Business net income is defined as net income attributable to equity holders of Sanofi excluding&#58;</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">amortization of intangible assets,</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">impairment of intangible assets, </font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">fair value remeasurement of contingent consideration related to business combinations or to disposals,</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">expenses arising from the impact of acquisitions on inventories</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">other impacts associated with acquisitions (including impacts of acquisitions on associates and joint ventures),</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">restructuring costs and similar items</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">other gains and losses (including gains and losses on disposals of non-current assets</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">),</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">costs or provisions associated with litigation</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">upfront payments and regulatory milestone payments recognized in the line item Other operating income and arising from transactions outside the scope of Sanofi's ordinary activities,</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">the share of profits&#47;losses from investments accounted for using the equity method, except for joint ventures and associates with which Sanofi has a strategic alliance,</font></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">tax effects related to the items listed above as well as effects of major tax disputes,</font></div><div style="margin-bottom:6pt;margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.55pt">net income attributable to non-controlling interests</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the items listed above.</font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">(1) Reported in the line items </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Restructuring costs</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">and similar items</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%"> and </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:120%">Gains and losses on disposals, and litigation</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">, which are defined in Notes B.19. and B.20. to our consolidated financial statements.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Free cash flow </font></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Free cash flow is a non-GAAP financial indicator which is reviewed by our management, and which we believe provides useful information to measure the net cash generated from the Company&#8217;s operations that is available for strategic investments</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (net of divestments</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), for debt repayment, and for capital return to shareholders. Free Cash Flow is determined from the Business Net Income adjusted for depreciation, amortization and impairment, share of profit&#47;loss in associates and joint ventures net of dividends received, gains &#38; losses on disposals, net change in provisions including pensions and other post-employment benefits, deferred taxes, share-based expense and other non-cash items. It comprises net changes in working capital, capital expenditures and other asset acquisitions</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net of disposal proceeds</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and payments related to restructuring and similar items. Free cash flow is not defined by IFRS and it is not a substitute measure for the IFRS aggregate net cash flows in operating activities.</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Amount of the transaction above a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div style="margin-bottom:3pt;margin-top:3pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Not exceeding a cap of &#8364;500 million per transaction (inclusive of all payments related to the transaction).</font></div><div><font><br></font></div><div id="i2456b270d3a64714a6867e4852c38438_166"></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  19                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><font><br></font></div><div><font style="color:#7a00e6;font-family:'Georgia',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Appendix 8&#58; CSR dashboards</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.698%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#23004c;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Affordable access</font></div></td><td colspan="3" style="background-color:#23004c;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#23004c;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sanofi Global Health Unit </font></div></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2022</font></div></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NCD</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:12.55pt">46,300 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patients treated</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:12.55pt">12</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> countries</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:12.55pt">54,396 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patients treated</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:12.55pt">19</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> countries</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Malaria</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:12.55pt">1,024,170</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> patients treated</font></div><div><font><br></font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:12.55pt">2,725,117</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> patients treated</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tuberculosis</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:12.55pt">35,094 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patients treated</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%;padding-left:12.55pt">3,022 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patients treated</font></div></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Rare disease vials donation</font></div></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2022</font></div></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"># Patients treated</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">998</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">1,065</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">#Vials donated</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">22,682</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">21,542</font></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Global access Plan</font></div></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></div></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"># of access plan</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Global access plan initiated for </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> assets</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">6 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Global Access Plans initiated or developed covering more than 10 indications</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.279%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="background-color:#23004c;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">R&#38;D for unmet needs</font></div></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Polio eradication</font></div></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2022</font></div></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%"># Inactivated Polio Vaccine (IPV) doses supplied</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">16 million</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> IPV doses supplied to UNICEF for GAVI countries</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7 million </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">IPV doses supplied to UNICEF for GAVI countries</font></div><div style="text-indent:36pt"><font><br></font></div></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Sleeping sickness elimination</font></div><div style="text-align:center"><font><br></font></div></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FY 2021</font></div></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FY 2022</font></td></tr><tr style="height:23pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"># Patients tested</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">million</font></div></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data updated annually at Q2 23</font></td></tr><tr style="height:21pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"># Patients treated</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">805</font></td></tr><tr><td colspan="9" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Pediatric cancer treatment development</font></div></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></div></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"># of assets identified</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;1 asset pre-clinical assessment complete</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;1 asset in protocol preparation for clinical study</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;&#160;&#160;&#160;&#160;1 additional asset identified for clinical development </font></div><div><font><br></font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:12.55pt">2 assets in protocol preparation for clinical study</font></div><div><font><br></font></div></td></tr></table></div><div><font><br></font></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  20                   </font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div style="margin-top:6pt;text-align:justify"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.977%"><tr><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.129%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.811%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#23004c;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Planet Care</font></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Blister free syringe vaccines</font></div></td></tr><tr><td colspan="6" style="background-color:#f4f2f6;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FY 2022</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">FY 2023</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">% blister free syringe vaccines</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">33%</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of blister free syringe produced</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Data updated annually in Q4 23</font></div><div><font><br></font></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Eco design</font></div></td></tr><tr><td colspan="6" style="background-color:#f4f2f6;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:36pt"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></div></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"># of Life Cycle Analysis (LCA) since 2021</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7 LCAs completed &#38; 1 in progress</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eco-design digital solution launched</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">7 LCAs </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">completed</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%"> &#38; 4 </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in progress (new products and marketed product)</font></div><div><font><br></font></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Scope 1 &#38; 2 GHG emissions reduction</font></div></td></tr><tr><td colspan="6" style="background-color:#f4f2f6;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">GHG reduction vs 2019 %</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">-29.4%</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">-30.5%</font></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Renewable electricity</font></div><div style="text-align:center"><font><br></font></div></td></tr><tr><td colspan="6" style="background-color:#f4f2f6;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">% electricity consumption from renewable sources</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">62.0%</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">62.6%</font></td></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Eco car fleet</font></div></td></tr><tr><td colspan="6" style="background-color:#f4f2f6;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">% eco car fleet on total car fleet</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">34.1% </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">eco-fleet</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">34.9% </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">eco-fleet</font></div></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.419%"><tr><td style="width:1.0%"></td><td style="width:16.877%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.635%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#23004c;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#ffffff;font-family:'Verdana',sans-serif;font-size:11pt;font-weight:700;line-height:112%">In and beyond the workplace</font></div></td></tr><tr><td colspan="6" style="background-color:#f4f2f6;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></td><td colspan="3" style="background-color:#f2f2f2;border-bottom:1pt solid #000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Diverse Senior Leadership</font></div></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">% of women</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">37.2% </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of our executives</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">41.7% </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our senior leaders were women</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">37.5% </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of our executives</font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:112%">42.1% </font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of our senior leaders were women</font></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Engagement with communities</font></div></td></tr><tr><td colspan="6" style="background-color:#f4f2f6;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"># volunteers</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">4,975</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> volunteers</font></div></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Next update in Q2 2023<br></font></td></tr><tr style="height:15pt"><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"># hours</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">26,906</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> hours</font></div></td></tr><tr><td colspan="12" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">From Leaders to Citizens</font></div></td></tr><tr><td colspan="6" style="background-color:#f4f2f6;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q4 2022</font></td><td colspan="3" style="background-color:#f2f2f2;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:36pt;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Q1 2023</font></td></tr><tr><td colspan="6" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">KPI</font></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%">More than half of the leaders have completed the initial eLearning phase</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">65%</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the leaders have completed the eLearning phase</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:700;line-height:115%">9%</font><font style="color:#000000;font-family:'Verdana',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> of the leaders have completed the full program</font></div><div><font><br></font></div></td></tr></table></div><div style="height:28.8pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">                                                                                                                                         </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">  21                   </font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>chart-7f33e0548ec048fabf5a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 chart-7f33e0548ec048fabf5a.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMY)=*\-^-;&"-=5\M#)(MK<6\LL<CJBL^Q_+<JK%58*2/T H **** "BBB@
MHKYZ_P""IG[>]I_P3+_8E\5?ME7WPND\91>&+K3H6\/1:P+!KG[7?06F?/,4
MNS;YV_[ASMQQG(R/^"1__!2&R_X*J_L?6G[6>G_""7P/'=>(+[2_["FUP:BR
MFV95\SSA##G=NZ;.,=30!].4444 %%%% !1110 4444 %%%% !117Y6?'K_@
M[T_X)L?L[_'/QI^S_P"-?@C\<;K6? OBS4?#VKW.E^&M'>UFNK*ZDMI7A:35
M4=HR\3%2R*Q4C*J>  ?JG17Y??LM?\'9G_!.C]KG]HSP7^S'\-_@O\:[+7_'
M?B*VT;2+O7/#FD1V<,\[A$:9XM4D=4!/)5&..@-?J#0 45X-_P %'/\ @H;\
M%O\ @F%^S3<?M3_'SPQXHU?P];:S::9)9^$+*VN+PRW#,J,$N;B!-H*G)WY]
M :_/K_B-6_X)9?\ 1 _V@/\ PEM#_P#EQ0!^OU%?,7_!+G_@J]^SM_P5L^$7
MB+XT?LY>#?&FB:5X9\1_V+?P>-].M+:=Y_L\4^Z-;6ZN%*;95&2RG(/&,$_)
M'QK_ .#MG]A#X>?$SQ+X/^$GP$^+/Q1\/>"[GR?%7CSP9H=NVE6P$A3S8WEG
M4O$65@LD@B1R,HS*0Q /U4HKRG]BO]M'X ?M_P#[.^B?M/?LU>*Y-5\,ZX)$
M475N8;JRN(VVRVMQ$23'*C<$9((*LK,C*Q\M_8__ ."NW[-O[<W[7/Q1_9&_
M9[\$^.-2N/A%-)!XK\>3:;9KX=>X6<P""WN%NVFE=W2?83 JLMM*P; 4L ?5
M%%%% !17R=^V_P#\%J_V"?\ @GE\??#_ .S1^TWXYUS3?%?B;1;75=)M=-\-
M7%Y%);7%U/:Q,TD:E5)EMY00>0 #T-?6- !1110 445\\?\ !1#_ (*D?L;?
M\$O?AK:_$;]J_P"(SV$NJO(GA[PUI%M]JU7670 N+> $#:NY=TDC)$I90S@L
MH(!]#T5^-6A?\'KW_!/2^\5+IVN?LR?&"PTAY=HU1;33)I44GAW@%X,#N0KL
M?3/2OU(_9U_;!_9Z_:E_9FT+]K_X2_$"&3X?^(;"2[LM=U>%]/6-(YG@E$HN
M AB*31R(2W!*Y!(() /3:*_/3]IC_@Y<_P""=_[.O[8N@?L7Z._B'XBZWKEW
MIUE+XB^'<NG7^D:?>7ER8%MIIVNT)EC^1Y!&KA1(!DN&1?T+H **_-'_ (*#
M?\'3O_!.[]@WXU:K^SO;:'XN^)/BOP]=M:>(T\&V]L+#3+I#B2VDN;B9-\R'
MAEB5U5@R,RNK*/0/^"7'_!PS^P=_P51\<R_!GX8GQ%X-\?QV<EU;>$?&EK#%
M)J44:[I7LYH)9(Y]B_,R$I)M#,$*HS  ^[J**\3_ &__ -OSX _\$UOV=;O]
MIW]I&761X=M=2M]/2#0--^U75Q<S;O+C1"R*,[&^9F51CDT >V45^-.G?\'L
M'_!/6Y\5)I^H?LP_&&VT9Y=IU/[)I;SHN?O- +W'N0)"?3/2OU/_ &3?VL_@
M'^V]\"-$_:1_9I\>P>(O">O1L;2\CC:.2&5&*R031. \4J,"K(P!Z$9!!(!Z
M/17Y%_'S_@\E_P""<WPC\>ZE\/\ P/\ !3XJ>+YM)OY;2\U*#3+*RM'>-RC>
M49KGS6&5/WHTKZ>_X)<_\%Z_V$_^"KVNW_P\^!^H>(/#?C?3; WMQX+\9V,5
MO=SVRD*\]N\,LL4Z*67(#B0 @E .: /M:BOBG_@JC_P7B_8T_P""2'BK0_AU
M^T!X<\;:]XF\1Z*=4TO1_"&CP2_Z-YKPB22:XGAC0%XW& 6;Y<[>1GYG_9T_
MX/'_ /@FG\8?B)8^ ?BG\._B%\-X-1NE@@\2Z[96MUIMN6( :X>VG:6)<G[P
MB=5&2Q4 F@#];J*BL;ZRU.RAU+3;R*XMKB)9;>X@D#I*C#*LK#A@0001P0:E
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *_##_@]S_:$\<>%/@G\$/V9M!U2>WT3QEKFL:WXABB
M<J+IM.2SCMHVQ]] U]*Y4\;DC;&5!'[GU^77_!U#_P $MOBS_P %#OV._#?Q
M,_9V\,3Z]X\^$6IWE_:>'+--]SJNEW<<2WL-NHYDG5K>VE6,<NL4BJ&=D4@'
MH7_! #_@G1^RS\"/^"5?PKU^+X,^&-5\0?$WP-9>)?&6O:IHL%S<ZDVH0K<K
M;R/(I)ABBE2)8ON#83C<[LWXF_\ !5KX=>&_^".W_!Q#H_CS]D/3T\-:39Z_
MH/B[2= TD>7!9Q79"7M@B+@+;RE;E/*&%6*?RP H%?2W_!)7_@ZP^$'[#G[&
M>B_L<?MQ? +XA77B/X9VCZ-H&H^%;&UD:ZM(F80VUW%=W%NUM+""(<@."L:D
M@,"#XE^RK\%_VG_^#DS_ (+4C]M_Q7\'[WP]\)=*\4Z?>^(+Z96>QT[2-.\O
MR-(CN&55N+N<1*KA!E6GEE*J@"T ?OS_ ,%+O^"5O[,G_!5KX;>'?A7^T_?^
M*+?3/#&N-JNFMX6U6*TE,[0M"0[20RAEVN> !SWK\!_^#<CX;>'?@S_P<>Z_
M\'_"#W+:3X4N/&^CZ6UY*'F-O:M/!&78 !FV(N2 ,G/ K]ZO^"I7_!6?]G/_
M ()'_"_PU\6?VD/!?C;6].\4Z^VD:?!X(TZSN9XYU@>8M(+JZMU";4(R&8YQ
MQCFOYG_^":G_  50_9\_8W_X+-^*_P#@HG\3O!WC*_\ !.NZSXJN[32]!T^T
MEU5$U.:9X \<MU'""HD7?B4@$':6H _L!HKS3]CK]JCX>_MN?LR>#OVK?A3H
MVLZ?X=\;:7]OTJR\0V\45[%'YCQXE2&65%;*'A788QS7<^,_%.G^!O!^J^-=
M6AFDM='TV>^N8[=09&CBC:1@H) +84XR0,]Q0!\\VW[$_P#P2M_X)^_LT^(M
M4O\ ]FSX8>$?A[H>CSW?BW5-<\/6]T9[8 F1KNXN5DFNV;.T"1G9BRHH)(6O
MP5_X-<?@GK?QS_X+?^(/VGOV??!5[H7PK\#KXBU">)E(AL[+44N;;3=,9LD&
M3$RN%R<BS=OX:\)_X*Q_\%Y/C'_P5P^+VG^#OB9=:UX#^ FEZTDMMX%\+F.X
MO)XE;_C[NC(\<=U=[<[%8K##GY03N>3]*?\ @CE_P<"_\$NO@[K'PP_X)L?L
M:_L-_$'PG:^,/%UAHRZWJU_I\TUYJ-Y+' =0OY4DWS2$E2Q PJJ$15150 'R
M+_P4/TVR_;1_X.U+#X.?&2U75/#"?%SPKX<ET:]&^%]+MX+-YK7:?^6<S>>S
M#N;A_6OI;_@]5_9H^#G@_P"$_P #OCIX(^'NC:)K4>NZAX>NKG2=.BMVNK(V
M\<\,3^6HW+$T3[ ?N^<^/O5XG_P<+_!3XV_\$T_^"Z/A;_@JIH/P[N]4\#ZY
MXK\/>*=/O8486K:CIZ6\5WI<TP!$4DJVID&>J7)*Y\MPO%?\%W?^"POAS_@O
M)XO^#'[+_P"P=\!?'MP^F:E=3G3-9TR#^T-5U:Z6***""&VFF'EQ(DA,C,,^
M:20JQ[F /VT_X)H_#_X<?\%'/^"&?P2^'W[7/A!/&&@:[X T2'7M,U*YE5=1
M;2;N(V[3-&RL^9;&&1@3B3!#AE9@?%O^#D/PM_P3:_9/_P""1?BWP#XA^ GP
M[T/6->MH]*^$VAZ)X8L[2ZCU021L+BT$,:M$L$8,DCKA=G[MB?-56],^,/[0
M-O\ \&]O_!#[P/J7B3P"WC'7/A[X1T7PVNEV5XL-M=:Y-&!+(\I!*VXG\YR5
M5F*X '.X?SD77_!2/P+^W!^W6/VN_P#@LDGC?XCZ'98;3?A_X%EAL[)8E?='
MIZ&693:6:]6$>9I226E#EI& /V<_X,N/V=OBU\,OV)?B-\<_'.GW5CX?^(WC
M"V/@^VNE*BYAL89(I[V,'JCRRF(-W-HW8 GU_P#X*2?'/_@F!_P;X?#?PKXE
MT;_@F[X>U_\ X61KFI133Z5I]FU]+/&J32/=7=ZLLTX8S8 9VV\@#'%=!_P2
M#_X+T?LR?\%)M9\2?L\?LQ?LP^(? -O\-O  U+3K'45LTLDM(7CMXK6"*U<[
M NY %  "K@=J^6/@?_P>S?LWOX/%G^U7^QGX^T/Q7:IY5Y#X'NK._LYIEX8X
MO)K:2W!8?</F%>FYL9(!\>?\$._ OP@_X*0_\%ZY?VT] O\ X?\ P6T31_%5
MSXG\.?![3]72._OY5MF$=M8PK'&DJ YGG957@2!8PI)3^H.OY3?V+X?BG_P6
M,_X.+-&_;*_9/_9\N_ GA*R^*>B>+?$8TV("UT+3=/\ LWG/<S1*L2W%X+5R
M4'^LFNG'SC<U?U94 ?D'_P '1G_!:W]JC_@FV/ G[.O[(4]MX>\0^.-(NM5U
M7QS=:=%=2V5K'*(4@M(YE:(2LV\O(ZL44)M +;E^>O@K\,?^"]/Q0\"V7QJ_
M8=_X.#OA9\9O%SZ>-0N/AW8>-;:[E9BF]K98+RW:(2#.TK/';A>Y6OHS_@X\
M_:L_X)<^'_C9X!_9$_X*G_LJ^*O$/AK5?"<FN^%/B?X&O FJ>'+M[J2WGA5"
MT>^)DAB=QOD!(3,#%48?AE^V%\)?V!K7X^> -"_X(B_%OXW>/=>U6_<_V?X@
MT 0ZE8WX>(V:V$MK%#++(3YI.(@4V(0[$G: ?TJ_\%<_AM_P5A^*?PD^&5K^
MPQ^UIX6^"D=K;W5Q\9/%OBG4+:TM[=?)M?)"RFVG=")/M/\ JBBG(W/C:1^-
M7[8O[='_  5J_P""7>J>'OB/\/\ _@OK\-_CY]JU46FH^'/"GC6T\0S6;*C2
M'[5931R!8&"LGFJP8,0/D)4UTG_!V!<_MQ:(?V7/"/[3^JZY/X.C^#FE?\):
M^GS?Z%>>-D+KK#DK^Z><1" QELX5W*<,]?/_ /P5F^(/_!#KQ;^QIX0T7_@D
MM^ROXUT;6M/\969\8_$'Q#I=Z8TB:PO,:;/=7-S*INI9 )A'& A6UD*G"XH
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M?7=.3P8VF60@%K!H]W/%'Y@@$V%EC1L[\_+R2.*_=:OY9?VY_C-XA_X),_\
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M-\/K+Q!_PC?@F^^R:U=::L*M)JEV@LA%-(R?OY8_/*JN[9$N-E?H9_P;7?\
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ME_P09T'QG#I]]>&?XB>/-"2PO=2-Q=2W"J'O-(E#&..0(JF0Y$8Y4' _</\
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M_:G^)=G#XO\ B+X+\&IB>SO;R'S+?3Y95CFE:6&U11Y,<4@&V68E1*-U_P"
M&B:/_P %UO\ @OG<?%O2-)MI?V:/V.XHM.\#V%I;JNFZEJD4A%NT2*-A22YA
M:X^4;3;V%JC ;Q7GO[7OQ0\,?\$MO^#M%OVVOVS8M3TCX7^-=!%QHOC%-(GN
MXXHG\.1Z8S*D*.[F*YB,3I&&=8Y%;;AAD _2/_@E)_P74^"W_!3GXD>+?V=-
M6^"?BKX3?%OP1!)<:]\/O& #3"".989FC?9&^^&5T22*2*-U,BX##<5^YZ_
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M_$_3-,ETWQY%X)TB)9+Z_O)X!IVG2+ H\V[C D.,%@+N-2<C:OVY_P '-/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB *H'H!BK=% !3+JUMKZVDLKVWCFAFC*2Q2H&5U(P5(/!!'!!I]% 'G?A_\
M9"_9-\)^*AXZ\+?LO_#O3-;642C6=/\ !5A#=!QT;S4B#Y]\YKN]8T71_$6F
M3:+X@TFVOK.X39<6EY LL4J^C(P(8>Q%6:* .0_X9[^ ?_1#_!__ (35K_\
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MAW79/%'A_P"'NAV&IS%_.U&STF&*=]YR^9%4,=QY.3SWK<HH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0W7[0?[+'[9>E?"G6M:W7FHZ#H?BVRTY+:=\LYGT;4E$EN <_+ 8H>#LR.:
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MK7;FTL_%<>EQ6,+PVTDFEA%DEMGFN8PK2EA!L .[>OTO_P $3O\ @MW\._\
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M^._"/@626,-K.OWVK:=$@=MJ@W5QI(B#-E=H95W=NHQZ=_P5=_X.,;SX:?\
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M436\T19?.MI=D99 RL&C1E88*M]BT4 ?SY?"'_@A=_P<]?L>>&9OV??V5_\
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M?B:XG\7> E8(_A^^N#YVGIW:SE;)CQU\ILQGG 0G>/SW.N!X23K9>[/^1_\
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M&[3QCX!\5Z;KFD7\?F6.JZ/?1W-M<)G&Z.6,E7&0>030!\<?L(?\$"?V#/\
M@G-^U#JO[67[-G_"96WB#5M,OM/;3-3UN";3K:VNIXYGCAA2W1D"F)%3+G"C
M'/6KFC_\$*/V)]#_ ."D;_\ !4ZRU7QP?B8^O3ZN8'UV$Z7]HEM'M&'D?9]^
MWRW.!YGWL'/:OH[XV_M7_LM?LSBS/[1_[2G@#X?C403IY\;^,K'2OM('7R_M
M4J;\>V:Z7X??$CX=_%KPE:>/_A5X]T7Q-H-^A:PUOP]JD-[:7*@X)CFA9D<9
M&.": /DS]KG_ ((4_L4?MJ_MI>'?V\?C#JOCB+QOX8;2FTV+1M=A@L2=/N#/
M!OB:W=F^<_-AQD<#'6O3O^"B7_!,W]D[_@J)\';3X,_M6>$;V\M-+U WVA:Q
MHU^;74-*N2A1I()<,N&0[61U=&PI*DJI'KGB#XP_"3PGXTT[X;^*OBEX<TSQ
M%JZJVDZ#J&MV\-[>AF9%,,#N)) 65E&T')4CM71T ?"O_!,7_@WO_8B_X)0?
M&_5?V@OV=O&WQ(UGQ#J_AJ?0IF\::[97,,5G-/;SN$2VL[?YM]M%AF+8&1WK
M\?/^#I[Q!H?[=/\ P6F\ ?L;?LZ^%;6^\;Z/HND^#=3U2$DM=:G?W33PVKD9
M'EV\=U&Q;JK33!ON<?TVU5_L/11>_P!HC1[7[1NW>?\ 9UWY]=V,YH XS]EG
M]GCP-^R7^SAX(_9G^&T&S1/ _AFTT>Q<H%:<0Q*C3N!_RTD<-(Q[L['O7>T4
M4 >'_MU?\$YOV/?^"D/PRA^%G[7/P@M/$=I82O-HNI1S/;:AI,S !I+:YB(D
MCSM7<F2C[%WJP %? &E?\&8G_!*73_%:Z_>?$[XUW]BLN_\ L.Z\6::MNW))
M0O'IR3;,8 PX;C[QSQ^M]% 'RO\ $[_@B]_P3Q^*/[!^G_\ !.+4?@D=.^&.
MB7)O/#EGINJS_;=(OB\KF]@NIFDD\\M/,2SEU82NK*RDK7RQ\+O^#/O_ ())
M_#S0-?TC7[CXF>+KK6K)[6TU;Q'XGMO/T<,P_>6JVUI#%YNT;=\J2XW$J%."
M/U/HH ^7/V)O^"1/[*G[ _[)?CG]C#X&ZCXLE\(?$*\U"YUZ77M7BN+Q7O;"
M&QF\J1(45!Y,*;<JV&R><XJC_P $PO\ @C3^R+_P24D\;2_LLZEXPN#X^731
MKO\ PE>LQ7>W[%]J\GRO+@BV?\?<N[.<X7ICGZQHH \X_:K_ &2/V=?VW/@S
MJ/[/_P"U%\+=/\6^%=2=9)=/OMZ-#,N=D\$L962"9=S 21LK ,PSAB#^:6L_
M\&7W_!*S4O$[:U8?%GXVZ=8O(7_L>U\4Z8T2<\(KRZ:\FWMRS-_M5^NE% 'C
M/[!_[!'[-_\ P3?^ </[.'[+GAN_T[PZFIS:E<G5-6EO+BZO)519)W>0X!*Q
M1C:@5!MX4$G/LU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'B"UTV/PAX;N98;@K,LA,Y:*VN&")Y8!_=G[PY%?F[_P9(?\F5?&+_LJ4/\
MZ;8*_:R@#^</_@G9_P %T?\ @IW^V/\ \%XO!'PO^,'C_6O!'@GQ3XRNK?4?
M@Z+-8[?2X(M-G,=JYFA6<N&B21V8J6<L=J@A1_1Y7\R?PN_Y7.+K_LMVL?\
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MG]NRV)NA9*TB,TGE!T\S"J<+N7)/45XOJW_!7GX.?LD?\$U/@;^VO_P4+O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFFS?Z[3]8T^.Y@D_WHY%*G\17SAXY_X(\_L2:_KC^,OAAX4UWX6^(3_J]?\
MA9XCGT>:+N-D:%H%P>>(Q7U'10!\A_\ #,O_  5,^!1\WX!?MT:#\1M-A_U'
MASXS^&3YNT=CJ-D?.D8CNP S^-'_  \!_;!^"H\G]KC_ ()N^,HK2+B7Q/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)_LT_P#!,CPM)=>+-3^W^)O$_B=;*]U34&52$CDG&JIF--SE4"@!I'8Y9B2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#\Y_^"XO_  68_:6_X)K7UM\+_P!G/]A3Q!\1=0U_
MP/<:K%X]MWNGTSP[,))H@;B&"TD\W8(_-*F:+@C) Y/S1_P:6?\ !1_]M_\
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M1^./P5^#L-O%\7/C!X6\*MJ,<IT]?$?B"VL3<A-N_P OSG7?MWKG&<;AGJ*
M/YQ?^#*2>:Y_X*-_%*YN9FDDD^"]RTDCL2S,=7TTDDGJ37],U?R[_P#!G#\5
M_A;\(?\ @H!\2=>^+'Q*\/\ A>QN?@[/;V][XBUF"RBEE.JZ<PC5YF4,VU6.
MT'.%)[5_15^UW^W)^SG^Q'^S1=_M<_'3Q?+'X$M&LMVKZ'9M?^:MW*D<#QK#
MGS$9I$(9<C!STH Y?_@K)^TIX]_8_P#^";WQC_:/^%@4>)?"_@FYFT&=HA(+
M:[D*P17!4@AO*:42X(P?+P>,U^"__!N!_P $A_V4_P#@L-HOQJ^/_P"WAXO\
M4>+O$.G:]:VD4$'BB6&[6>ZCEFEU*XER9)I'8;4+DIF.7<KY&W]Z/V>_VF?V
M,_\ @L1^QKXB\2_#H7'BCX7^+(]2\,:];ZWIDMB;A/*"7,963#J-LHPXP0>0
M01FOQ7UO_@@O^QQ^R=K6K_M-_LY?\''6D?#7X:7%J\LFI>']8@DU62PR6%I'
M<Z;JD0OV8#"A(LLQ&(F/! .4_P"#>CXL_%3_ ()Q_P#!>SQK_P $M;;X@7^J
M^ M<\6>)_"]U9W4I\B2\TM+J:TU-8Q\L<[QV?E,5 RMQAL[$*^G_ +27PH\$
M?\%)/^#O"^_9/_;6L;GQ!\/?"?A];;P]X.NM2GMX)(8O#<>HK&IB='"O<S27
M+;""X7:V5!%?/7_!K]^SGJ7[2'_!;_4?VFO $OB;5_ GPQ.O:V_B7Q9,)KZY
M^W17-C8)>3 ;7O)5N7G;&-QMY2.!7[0_\%,O^"!7[-G_  47^.&C?M7:=\7?
M&_PG^+&BV<=I%XX\ 7RPRW44881&9" WFQJS(LL;QOL.UBZJ@4 _/'_@CEX8
MT;]AS_@Y]^/'[$_[,US=6'PHFT34ENO#W]H2SVUFL$5I=PLS2,Q+6\LLMNKN
M2P65U+$L2>D^!?Q'^'W_  6+_P""WOC7_@I9\<_'&DZ3^R_^R(B67@K6?$>H
MQVNDW6HQRM]GNVEF98\/<"2^WY#!8[&-@=PK!_X*-_LA? ;_ ((!?LG>(?A[
M^RUX\\9_$C]J+]K2XD\&VGB_Q'>+/JXTN>:,ZB;9(E!0S/)!#N9GE>:X1P_[
MK:/'O^"_'[&/B#_@EI_P1H_9>_8B\+W!6WU7Q9J>N_%B^LF(BU7Q-]C@8%V'
M$B1B:>*+/6.UC.,KF@#]V_V>/^"I?_!.O]K'Q\?A7^SI^V3X"\5^)2CM#H.F
MZ[&+NY5 2YAB?:TX4 DF,-@#)XYKWROYN/\ @XU_9-_93_X)U?$O]C?XF?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>7!'8U\__%/_ ()O> M=$VI?"?Q)<:%<D%H].ORUS:$X 50Y/FQC.26)E//
MKZ4HK>CB:^'=Z<K?E]PC\W/BI^R]\;/@]YMWXJ\&32Z=%DG5]-_TBUV@@;F9
M1F($D8$@0GTKSZOUE!*D,I((/!%>8?%#]C_X#?%5I+S5/""Z7?R'+:EH16VE
M)W%B64*8W+$\LR%CZBO7H9STJQ^:_P AZ'YTT5]#?%#_ ()T_%?PJ'O_ (=:
MM:>)K11GR.+6[7@D_([%& P!P^YB>$KP77_#GB#PIJDFA^*-"O--O8<>;9W]
MJ\,J9&1E' (R.>E>O1Q-#$*].5_Z["L4Z***W **** "BBB@ HHHH **** "
MOW^_X)?V#Z;^P%\+K>1<%O#8EQ[22R./T:OP!K^BO]BWPT_@_P#9!^%_AN5-
MLMKX TA9QCI(;2)G_P#'B:^!\0)I8"C#O*_W)_YGI98OWLGY'IM%%%?E)[04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%?S5?\ !?OQG^TG_P $I/\
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MI[&60M"4@HHHK\]/4"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\J?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;]LC5/C)-XKUNWU&QU34]/GMS81QP>68E$UW<E@Q.[(91['K0!]F445^2_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP]HOB*^NY8=5>ZM'BN2D^FVRA5ACN4+!R<R@;2"2/M?]KW_DTWXH?]D[UO\
M]()J]$KX"_X*_P#_  1)\>_\%3_B9X:\>>&/V^O%7PEL="\,RZ1>Z%H6BRW<
M&I[YGD,LFR^MQG:^S:5;('7M0!^:O_!CS_R6O]H+_L5M!_\ 2F\K]CO^"L?[
M,?[,?[:G[*0_9*_:L^/2_#W0/'?BS3;/3M4BU:TL[F]OX)#>QV5LUV&C::1+
M:4A-K,51B <5^8_@;_@R]\1_#&>XNOAK_P %</%OAZ6[15NY-#^'CVC3*I)4
M.8M67< 2< ],FOT5_P""JG_!)'P;_P %4/V,/#7[(OCSXUZQX7?PKKUAK.G>
M)M/TV.Z::[MK&YLQYT,CC>C)=2,5616W!?FP"" ?F7_P5%_X-1_^"='[(_[!
MOQ%_::^%7[1_Q$T+7? 7A:YU6Q;QMKFG75CJLT2%H[)ECLX&$UPX6&,HX_>2
M)\C=*[[_ (,K_P!IKX]?%C]G/XO? 7XE>)]1U?PG\.M6T1_!$FHS-+]@%]'>
M_:;.)VR5A0VL,BQ@[4,[D ;^>"A_X,L/BGXBO[+P[\3?^"JU_J?A;3Y%^SV2
M> 9WD5 ,;8XY=3:. XR 1N ]#TK]=O\ @G3_ ,$Y?V;?^"8/[.MK^SC^S5HE
MVEA]K:^UO6]6F66_UF^=51KFX=552VU$5515150  <D@&Q\!/^"@O[#_ .U-
MX^O?A9^SC^U9X%\;^(].T^6^O]$\->(H+NY@MHY8XI)GCC8D(LDL:$] 74=Z
M\M_X*M?\%B_V4?\ @DW\)'\5_&+7DUCQGJ=H[^#_ (<Z7=+_ &CJ\G(5VZ_9
MK8,,/<.-HPP02/A#X+_P2!_X-TM%_P""3O[7WB?]K#3_ -K:Z\=2>)/!U]H#
M:%-X(73EMQ<WUG=^=YPO)MVW[($V[!GS,Y&,'S/_ (*5?\&I&E?\%&/VU_&W
M[8^K_MY:CX8D\83V;IX>_P"%>K?K8)!9P6PC69M0CW ^27^XN-Y&#C) /F3_
M ()6_P#!+7]KW_@M-^W/'_P67_X*AZ*^E>!I-7M]6\)>%;FU:'^WUMRIL;>W
M@?)BTJ$*AWODW..-_FR2C]6/^"S7_!)/X=_\%?/V8;7X*>)/',OA/Q'X=U@:
MMX/\516(NEM+GRVCDAFAW(9()4;#!65@R1N"=A5OS<7_ (,E510B?\%3]?"@
M8 'PQX _\&M?M#^RI\#O^&8_V8?AS^S?_P )9)KW_" >!=)\.?VY-:^0^H?8
MK.*V^T-'O?RR_E;RNYL;L;CC- 'Y%^*O^"#/[6GB'Q;X0_:D_P""WW_!3;2?
M'WPG_9QT:75+#1=*T,QL^G6BQSR13RF*' D%M$)9")IYEC5-X)5U\?\ V*?$
M7QT_:&\,_MC?\'.OQ"T26U\0:9X/U_2OV=[.^B$JZ*(K1H!=QJ1M86L/DV^X
M?+([7NX9)-?KQ_P5F_X)^^./^"FW[)=W^R3X9_:6G^&.E:UJ]M<>)]1M/#/]
MIRZG:0,9%L]IN8/+0S"&1FRQ/DA<8+9[[X5_L2?L_P#PH_8JT[]@32O!\=U\
M.K/P*_A2\TNXX-_92P-#<M*5QF2?S)7=Q@EY6;J: /YP/@!_P2I^!?[2W_!
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M#8'>Y2),O=::?FE7W,9S(/;S,<D5^6]?OW)''-&T4J!E8$,K#((/4$5^1_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXS^/WA8_\%)/#DOPGU9/#CS^%/"'@R]^QV*V;SLLDX$%W<.[-)%M)EE9L1@
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M(BA411@*!T ':OEL]S513PU%Z_:?Z?Y_<>I@<)=^UG\O\QU%%%?('L!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@72O^"L&JVO@B]G,EYI%M\/ID\_MAX1J@A9MO&\@_P"[VH _;'X"_M*? O\
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MZW\,[^;5/AO_ ,%:O%7A^ZN(?*N+G1/ATUI)+'D'8S1:LI9<@'!XR* /:O\
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MSH>N:;;WME>V[P7EG=PK)%/$ZE7C=&!#*RD@J0002#5'P3X#\#?#3PY#X/\
MASX,TGP_I%LSM;Z7HFG16EM$78LQ6*)5526)8X'))/>I?"+,_A/2W=B2=.@)
M)/)/EK6C0 45\^_\%,_^"B_P0_X)?_LI:W^TU\:+M;A[<?9/"WAN&<)<Z]JC
MJQALXLYP#M+.^"(XT=\' 4_R[?M ?M&_\%/-7_X*%_#?XQ?M?_%;Q;X?USXO
MZIH/C"R\+V6OW5K;V.CW>HF&T@%JKA8(_)MP4C.6\ID9R79J /["Z*_._P#X
M.?\ ]M+XV?L2?\$L]3\7?L_>++WP]XD\9>,-/\+1>(M,E,=UIL$\5S<3RP2#
MF*1H[5HA(,,GFEE*L%8?D1^VC^P1XQ_X)5_\$T/V:/\ @L/^S3^V7\48/BU\
M1+[0+KQ5-=^(E>U:75-'GU9!$JQAWC3R##(D[S+,')8 94@']0]%?E7_ ,%L
M_P#@KAXT^%/_  2%^&K_  @6XM?C-^U/X1TFS\(Z5HI?[78QW]E;RWT\ 4[P
MZBY2VB*G>);J-ER4-?6W_!,#]F[3_P#@G;^Q-\/OV;?C-\8DU+QW<V7]H>+-
M1\0^)//N-0UBXP]PD332%I(XCMMX]O5(5.,DY /IZBBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *JZWH>C^)-+FT77]-AN[2==LUO<1AE8?0_P ^
MU6J*:;B[H&DT?,_QA_8PU33&FU[X42M=VW+-I$[_ +Z,?],V/WQ['#>[&O"+
MVRO=-NY+#4;26">%RLL,T95T8=00>0:_0^N6^(WP9^'OQ3MC'XKT)&N NV*_
MM_W=Q'Z8<=1[-D>U?28#B&K2M#$+F7?K_P '\SS*^71EK3T\NA\*45[/\1_V
M+O'OALR7_@>[CUNT&2(.([E1_ND[7_ Y/]VO']3TO4]%O7TW6-.GM+B(XD@N
M8BCJ?=6 (KZK#XS#8N-Z4D_S^[<\JI1JTG::L04445TF84444 %%%% !1110
M 4444 %%%% !176?#_X)?$OXF.K^%_#,S6Q.#?W/[J!?^!M][Z+D^U>^?##]
MB[P=X;\O4_B%>?VU=K@_98\I:H?I]Z3\< ]UKSL7FN"P:M.5WV6K_P"!\SHH
MX6M6V6G<\%^&'P2^('Q8NPGAG22MHKXFU*ZRD$?K\V/F/^RH)KZE^#G[.?@C
MX1PI?Q1#4-8*XDU.XC&4/<1KR(Q^;'N<<5WEE8V6FVD=AIUI%;P0H%BAAC"H
MBCH !P!4M?(8_.<3C;P7NP[+KZO^D>QA\%2H:O5A1117CG8%%%% '\Q__!W9
M\9_B/\?_ /@JYX,_8[37WMO#_A/PUI=MI%C+(?LZZCJDN^:\8=R8S;1D]E@X
MZG/ZO?$7XG?\$1/^#?/X2^!?V8?BYX-TGPW#XAT.7[-?CX?2:K>>(3;^7'<7
M5[/#!(TDCM*I(<X ;:@"*%'Q)_P=U?\ !)WX^?$;XD^'O^"F'[-'@O4_$$&E
M>'8=(^(>GZ#;O+>:;]EEDDMM46- 7>/9(8Y&7_5"")B-I=E\SUK_ (../^"6
MW[=O[,NG:!_P55_8-U'Q%\7_  YX/O-,T;Q3IV@66I:>UY)!@W47FW$,MH9)
M4C=HPDBJ1PY % 'Z)_\ !(;XQ?\ !"_X]_MI?$;XP_\ !+*TFT;QKJ7@F/\
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MFC^Q7^V+X+_9Q^'W@_6+[2/%'Q8\5ZC:V;7=U9!EO)#=7'^K03(T,$4!1Y6
M=I CXC^=/^#.#_E+[\0/^R,:Y_Z>=(KS3]N_]D_P%_P2[_X+9>*_'7_!2?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K^9/_ (-3/^4[GQ._[$7Q5_Z>+&OVC_X*
M_?\ !*7QW_P5(\-^!= \#_MI^)?@V_@V^O[BXN?#>FRW+:H+A(%"2".\MMH3
MR21DMG>>!W_//PI_P98ZQX#UZ7Q3X&_X*S>*=%U2>-TFU+2?ARUM/(K$,RM)
M'JP8@D D$\D T ?NK7\TO_![5_R?C\)?^R1_^Y2\K][O!7[(OB#PC_P3UMOV
M&[CXXZI?:G;_  H?P:?B-+:N+QYFL&M/[2,9F+>:&;S=OFYR,;_XJ_)?QO\
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MQ\3_ +&?QCT,L^D6]CJT8Y4V=V$?'NLNWGV!-?7=%>M0SW,:&CES+SU_'?\
M$Y*F!P\^EO0^!]=^&?Q#\,LPU_P1JMJ%ZR2V+A/P;&#^!K#Z=:_12L_4_"7A
M36V+ZSX8T^[+?>-U91R$_P#?0->G3XG?VZ7W/_@?J<LLK7V9?@?GW17W1=_
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MO'?ACQ=X\^)'BBU2YTCP%X"TV.YO%@>1HXI)C)(BH)'1U1%WR,5)V8^:F_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW?VQOBG/\;/VF?V3O#WB_P 57-G#:SZUJ4]TLKPQ+MC0B.55PHX'%;O[)/\
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MM$:KX"7X42Z-XLN;?3-.:X&OQP:E$QL92MQ%Y:-LP6(D W?<- 'VO^WSX_\
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M?!/X1_LS^&+S4/!WP+\1PIXF:TM27,4]I,DNKW"KD#?=LS2-T5[SLN<?+O\
MP6L_X* _LZ_\%D/@W^R/^QQ_P3^L]7\6?$.S"VVJZ GARZMFTB[FL[.V6RWR
MQJLN&CD9Y(2\2I!N+XZ '].5%4?#&E7&A>&]/T2\OFNI;.QB@EN7ZRLB!2Y]
MR1G\:O4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9BJJS#\P[[_@]A_X)[0>*C86/[,'QAGT=9=O]I&UTM)V7/WA ;W'N 9![XH
M_6_5/@A\%M<U&?6-:^$/A>\N[F0R7-U=:!;222N>2S,R$L3ZFGZ'\&?@_P"&
M=5AUWPW\*/#6GWUN28+RQT*WBEC)!!*NB C()'!Z$U\\?"__ (+.?L,?&#_@
MGYXE_P""EG@CQ=KLWPV\'/+!XE\[P[-'J%C=1^1NMC >))/])@^:-FC_ 'GW
M^&Q\(>(/^#V/]@"S\0-9^&_V6?B]?Z:L@7[?<PZ7;RL,\L(A=N,8Y&7!/?%
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MYI$:0(K-LD\MFVG:&Q7Z%4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOXAU71IK:7PIX@_LR;0KAW0KY4]QYQD>$D_-_HV2.PH K?\ !E]^R5X6\"^
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M1I>G2K;K^]NEVSL$(+JMU&/X@!]O_P#!S/\ \%\/C3_P3FUO3_V)OV5?#?\
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MA_QIKGB'Q/I<FH:/HWA#1X9BT"2&(O)+<3PQH-X(P&9N,[>E?(OPJ_X/2O\
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MXG^%GPP\;:@NK>,_AQH.KW20B)+G5-'@N)%C!)"!I%)"@LQQTR3ZUG?\,]_
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^U-J7C"W/@ :D-"_X1368K3=]N^R^=YOF02[_P#CSBVXVXRW7/'X@?\ !EK
MEK_P5'^)EM%G;'\#M25<]<#6]'%?M?\ \%6O^"UO[+'_  1]?P&G[2_@'X@:
MX?B&-4.B_P#""Z58W/D?8/LGG>?]JO+;;G[9%MV[\[7SMP,_S>_\&^W_  5/
M_9\_X)1?MH^,OVC/VB/!WC+6=$\0_#J\T"RM?!>GVEQ=)<RZC872NZW-U;H(
MPEK("0Y.XJ-I!) !^[O_  =@?"_XD?$S_@C;XOF^'>EW5ZGAOQ/I&M>(+:S0
MNYTV&8I+(57DI&TL<K'HJQLYP%)'Y4?\%'O^"B/[$?[0'_!NC^S1^Q5\%_'-
MKK'Q3\/:IH$6K>#K/3)A=:9/9:?>6UU,Q,87][-,H7:Q,GGY .&Q_29\#_BQ
MX/\ VE_@%X/^.?A?2+N/P_\ $#P?I^NZ=8:U;QB=;.^M8[B.*=$=T#^7*%=5
M9USD!F')^>?VA/V>O^"5/_!-7X7>,_\ @H?J?[%/PF\.7O@/29=8_MO1_ >G
M6MZUT#B&*VD6$>5<3SO'$K+M)>49/- 'Y?\ _!2?Q/\ '_\ :0^%?[&?_!ME
M\,-3N+7QSJWP]\(W'QZN!ESHT-IIL!%O< 'D0K#/>R(V"?(M,<R8KV*Q_P"#
MDG]GW]F'3M2_94_X)L_\$W_B7\8/A?\  '1(M*U_QIX8D:*PTRPM%:(WA,5K
M<9A/DR-]HG,/FE9).F6.A_P;8_LC_%3X]:/\7O\ @LY^U&S)\2OVA[W4+7PA
M=2QG.EZ,9"KRPAN41YHXXHU_A@L(MIVR5\)?\$4_^"@'[.W_  1N^#G[7'['
M/_!0*SU?PG\0[P&VTKP_)X<NKEM7NX;.\MFLM\4;+%EI(V228I$R3;@^.H!^
M^O\ P3;_ ."C/[/_ /P5$_9ELOVG/V>I=0@L'OY=-UK1-8B1+S2-0B5&DMI@
MC,I.R2.165B&21#P25'OE?C]_P &97P%^*7PO_X)Z>-?BEX]T&\TW2O'_P 0
M3>>%(KR)D^V6EO:10M>1@]8WEWQAN_V<GI@G]@: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,3Q[\-/AS\5-#/AGXG^ -$\2::S;FT_7M*AO("?7
MRY59<_A7/?#7]E?]F'X,ZR?$?P?_ &<? ?A3460HU_X:\(65C,5(P5WP1*V"
M.V:[RB@"KK.B:-XCTN;1/$.D6M_97"[;BSO;=98I1G.&1@0PR >1VKFO^&>_
M@'_T0_P?_P"$U:__ !NNOHH Y[P[\(_A1X/U-=;\)?#'P]I=ZBE4N].T6""5
M5(P0'1 0".O-26_PO^&=IXF/C6T^'>A1:R96E.KQZ1"MT78$,WFA=^2"03G)
MR:W:* ,?Q7\/? /CSR/^$X\#Z/K/V7=]E_M;3(KCR=V-VWS%.W.U<XZ[1Z5D
M?\,]_ /_ *(?X/\ _":M?_C==?10!%86%CI5C#I>EV4-M;6T*Q6]O;QA(XHU
M "HJCA5    X %5O$/AGPWXNTM]#\5^'['5+*1E:2SU&T2>)B#D$HX()!Y'%
M7J* (-,TO3-$TZ#2-&TZ"TM+:(1VUK:PK''$@& JJH 4 = .*Y#XC?LU?LY?
M&'7;;Q3\6_@!X)\4ZG9*%L]1\1^%;.^G@ .0$DFC9E //!'-=M10 RUM;:QM
MH[*RMXX888PD442!510,!0!P !P *?110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>imagea.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 imagea.jpg
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J=PU<#\/^4J5*E2I5JE2I4J7FMIS['Q-1/-?G =S"     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ratingagenciesq123a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ratingagenciesq123a.jpg
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MQFGEFIK1DE^"BRYN\'GQ-?B\/@ 5"6UA\4IU!,PE81=P[K&GX/?.^ZA,3I'
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M%K#,[:VLK+!TZ3()X9J" H.P9LU:6-N<1>UUYH4U%3#'1J?BPT&3<?=?!_T
ME@W _#X>NG<P3APYBPI1>8\Z8R/ F /]V!VC#3#/%\ \;S6>VCH&![S^>&/
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MA(6;MPRJ]H9,UB5CWKQY.'3HD(3CZ=.GP]G94. 8*0X/#Y=0RQ=8$(09229
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M>T<*F+M9"ICUJ:M]F./CDK%AS3[LV<&^RR=@;>&$?;M.8,W*/3BTWPH[MYZ
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M3(NI&YBK*FL0$9R(J+!D9<J4*5.F3)DR9<KZI(4+7DU/R342;-=D,F".C\I
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MC(_?=$4:,$U6IQV[HD%6>W(G2L>\(VP@2L>]BY+1 U VY6,T!+H9M[AYU)W
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M,'" &:>+8]<,/N+F!-?<AOUB^E+_1E.K.X#Y5I8"9GU2P*Q?"I@[+P7,^J6
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M'OZ&'M +'4&Q01IPCN_C6Z2E5][FR8^^N<[WTBLZ**U.E3RE8V?\ENN>6;$
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MTS6OV!1#\YO9"MLCG_));,5?-D?6U090.R!8("<?;U M)A1GQ3IM*@X;<+*
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M=EDCF,X9:5?/>K9\7%=7A!I9!.13.N66?]73L?/R=?[[W_]^NU?=E-DSG4=
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H"((@")9!"',0!$$0!$$0+(EA^/\#0$.>U>DD50    !)14Y$KD)@@@$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
